Method of treating an intraosseous nerve

Information

  • Patent Grant
  • RE48460
  • Patent Number
    RE48,460
  • Date Filed
    Friday, March 24, 2017
    7 years ago
  • Date Issued
    Tuesday, March 9, 2021
    3 years ago
Abstract
This invention relates to a method of straddling an intraosseous nerve with an energy transmitting device to improve the therapeutic treatment of the nerve.
Description
BACKGROUND OF THE INVENTION

In an effort to reduce back pain through early intervention techniques, some investigators have focused upon nerves contained within the vertebral bodies which are adjacent the problematic disc.


For example, PCT Patent Publication No. WO 01/0157655 (“Heggeness”) discloses ablating nerves contained within the vertebral body by first boring into the vertebral body with a nerve ablation device, placing the tip of the device in close proximity to the nerve, and then ablating the nerves with the tip. Heggeness discloses using laser devices, electricity transmitting devices, fluid transmitting devices and thermal devices, and devices for carrying either chemotherapeutic or radioactive substances as candidate nerve ablation devices.


In describing techniques using electricity transmitting devices, Heggeness discloses “raising the temperature of tip 24 such that the intraosseous nerve is ablated by the heat generated by electrical current passing through tip.” See Heggeness at 8,28.


Heggeness further discloses multiple methods of accessing the intraosseous nerve (ION). However, each of these methods essentially disclose either i) boring a straight channel into the vertebra such that placement of an electrode tip near the end of that channel will bring the electrode tip sufficiently close to the ION to effect its ablation, or ii) accessing the basivertebral nerve (BVN) via the vertebral foramen. None of these techniques recognize how to effectively carry out nerve ablation when the precise locations of the ION is unknown, or when the electrode tip can not be maneuvered relatively close to the ION.


EPO Patent Published Patent Application No. EP 1 059067 A1 (“Cosman”) discloses ablative treatment of metastatic bone tumors, including those within the spine. Pain relief is reportedly achieved by penetrating the bone wall with a suitable probe, and applying heat through the probe to ablate either the bone tumor or the tissue near the bone tumor. Cosman teaches the use of both monopolar and bipolar probes in this application. Cosman also teaches that the treatment may also be used to ablate the nerves and nerve ramifications in and/or around the bone to desensitize them against further tumor encroachment. See Cosman at col. 11, lines 7-11.


However, monopolar approaches require the use of a grounding pad beneath the patient and allows energy to flow from the probe and to dissipate in the surrounding tissue. Because the path by which the energy flows from a monopolar probe to its corresponding pad is uncontrolled, the energy may undesirably flow through sensitive tissue, such as the spinal cord. Since this method may cause undesired local muscle or nerve stimulation, it may be difficult or dangerous to operate in sensitive areas of the human body.


Cosman discloses devices whose electrodes can deviate from the axis of the access channel. In particular, Cosman discloses steerable tips, spring-like electrodes that take a straight shape within the catheter and then curve upon exiting the catheter. Cosman discloses that the curved portion of the electrode may be a rigid and rugged permanent curve, or it may be a flexible configuration so that it can be steered, pushed or guided by the clinician to be positioned at various location. See Cosman at col. 8, lines 40-50). Cosman discloses that electrodes may comprise tubing made of elastic or super-elastic metal such as a spring steel or nitonol tubing so that the electrode can be inserted into straight segments of the cannula and still describes a curved path when the curved portion emerges from the opening. See Cosman at col. 10, lines 11-16. Cosman also discloses an electrode having a flexible but steerable tip which can define an arc, as set by the physician. See Cosman at col. 14, line 3.


In sum, Heggeness and Cosman disclose methods of treating that assume the tip of the electrode can be directed substantially to the target tissue.


A few investigators have examined the effectiveness of heating bone with monopolar RF electrodes. DuPuy, AJR: 175, November 2000, 1263-1266 noted decreased heat transmission at a 10 mm distance from the electrode through cancellous bone in ex vivo studies. DuPuy notes that local heat sinks from the rich epidural venous plexus and cerebrospinal fluid pulsations may account for the decreased heat transmission in cancellous bone. Tillotson, Investigative Radiology, 24:11, November 1989, 888-892, studied the percutaneous ablation of the trigeminal ganglion using RF energy, and found that bone marrow necrosis was limited to a sphere of about 1 cm in diameter, regardless of the probe size and duration of heating. Tillotson further reports that Lindskog showed that the transmission of heat within bone is sharply limited by blood flow, and that lethal temperatures cannot be sustained over great distances.


In sum, these investigators appear to report that the well-vascularized nature of bone appears to limit the heating effect of RF electrodes to a distance of less than about 0.5 cm from the tip.


U.S. Pat. No. 6,312,426 (“Goldberg”) discloses a system of RF plate-like electrodes for effecting large, uniform, and extended ablation of the tissue proximate the plate-like electrodes. In some embodiments, the plate-like electrodes are placed on the surface of the body tissue, where the ablation is desired, and are configured to lie approximately parallel or opposing one another, such that they make a lesion by coagulating most of the body tissue volume between them. Goldberg appears to be primarily directed to the treatment of tumors. Goldberg states that one advantage of the system is that the surgeon need not determine the precise position of the tumor. See Goldberg at col. 3, line 59-60. Goldberg does not appear to specifically discuss the treatment of nerves.


U.S. Pat. No. 6,139,545 (“Utley”) discloses a facial nerve ablation system including at least two spaced apart bi-polar probe electrodes spanning between them a percutaneous tissue region containing a facial nerve branch. Utley teaches that the size and spacing of the electrodes are purposely set to penetrate the skin to a depth sufficient to span a targeted nerve or nerve within a defined region. See col. 5, lines 44-47. Utley further teaches that the system makes possible the non-invasive selection of discrete motor nerve branches, which are small and interspersed in muscle, making them difficult to see and detect, for the purpose of specifically targeting them for ablation. See col. 2, lines 20-24. Utley does not disclose the use of such a system for the treatment of IONS, nor rigid probes, or deployable electrodes. The probes of Utley


SUMMARY OF THE INVENTION

In attempting to place an electrode in close proximity to the BVN, the present inventors have found the approaches disclosed in the teachings of the art to be somewhat problematic. In particular, although the location of the BVN is somewhat well known, the BVN is radiolucent and so its precise location cannot be easily identified by an X-ray. Since the BVN is also extremely thin, knowingly placing the electrode in close proximity to the BVN may be problematic. Moreover, since conventional RF electrodes appear to heat only a fairly limited volume of bone, misplacement of the electrode tip vis-à-vis the BVN may result in heating a volume of bone that does not contain the BVN.


For example, and now referring to FIGS. 1 and 2, there is provided a representation of a treatment scheme involving the placement of a conventional bipolar electrode device in close proximity to the ION. In these FIGS., the ION is represented by the solid line identified as ION, while the vertically-disposed dotted lines identify the edges of the zone within which the practitioner believes the ION likely resides (i.e., the ION residence zone, or “IRZ”). As shown in FIGS. 1 and 2, if the ION is substantially in the center of the ION residence zone, then placement of the bipolar electrode either on the left hand boundary of the ION residence zone (as in FIG. 1) or substantially in the middle of the ION residence zone (as in FIG. 2) satisfactorily locates the electrodes in a region that allows the current flowing from the electrodes to flow across the ION. Since the current flowing across the ION may resistively and conductive heat the local bone tissue and the ION will be heated to therapeutically beneficial temperatures, these scenarios may provide beneficial treatment of the ION.


However, and now referring to FIG. 3, if the ION is substantially at the right edge of the ION residence zone, then placement of the bipolar electrodes on the left hand side of the ION residence zone fails to locate the electrodes in a region that allows the current flowing from the electrodes to flow across the ION. Accordingly, current flowing across the electrodes can not resistively heat the ION. Moreover, since bone is a heat sink that effectively limits the heat transport to about 0.5 cm, the heat produced by the electrodes may be effectively dissipated before it can reach the ION by conduction.


Similarly, and now referring to FIG. 4, if the ION is substantially at the left edge of the ION residence zone, then placement of the bipolar electrodes in the middle of the ION residence zone fails to locate the electrodes in a region that allows the current flowing from the electrodes to flow across the ION. Again current flowing across the electrodes can not resistively heat the ION, and the heat sink quality of bone may effectively dissipate the heat produced by the electrodes before it can reach the ION by conduction.


Moreover, even if the precise location of the BVN were known, it has been found to be difficult to access the posterior portion of the BVN from a transpedicular approach with a substantially straight probe.


Therefore, the present inventors set out to produce a system that allows the practitioner to heat the BVN without having to know the precise location of the BVN, and without having to precisely place the electrode tip next to the portion of the BVN to be treated.


The present invention relates to the production of a large but well-controlled heating zone within bone tissue to therapeutically treat an ION within the heating zone.


Now referring to FIGS. 5-6, there is provided a representation of an embodiment of the present invention in which electrodes E1 and E2 respectively disposed probes (not shown) therapeutically treat the ION. FIG. 5 provides a schematic representation of the electric field EF produced in the bone tissue by activation of the electrodes. In this case, the electric field is relatively thin. FIG. 6 provides a schematic representation of the total heating zone THZ produced by the electric field of FIG. 5 including both an inner resistive heating zone IR (represented by open circle) and an outer conductive heating zone OC (represented by closed circles). In this case, the inner resistive zone is produced by the joule heating of bone tissue disposed within the electric field EF, while the outer conductive zone is heated by conduction of heat from the resistive heating zone.


Still referring to FIG. 6, the present inventors have found that positioning the active and return electrodes of an energy-transmitting device in a manner that allows the electrodes to straddle the ION residence zone IRZ provides a large but well-controlled total heating zone (IR+OC) within bone tissue to therapeutically treat the ION within the heating zone. Since the total heating zone is large and the electrodes straddle the IRZ, there is a high level of confidence that a portion of the ION will be present within the total heating zone. Since the total heating zone is well controlled, there is no danger (as with monopolar systems) that current flowing from the active electrode will undesirably affect collateral tissue structures


Now referring to FIG. 7, if the ION is in fact substantially in the center of the ION residence zone, then placement of the bipolar electrodes in a manner that straddles the ION residence zone allows the production a total heating zone between the electrodes that includes a portion of the ION therein.


Moreover, the present invention allows the practitioner to therapeutically treat the ION even when the ION is in fact located at the edges of the ION residence zone IRZ. Now referring to FIGS. 8 and 9, if the ION is located substantially at the right edge (as in FIG. 8) or the left edge (as in FIG. 9) of the ION residence zone IRZ, then placement of the bipolar electrodes in a manner that straddles the ION residence zone still allows the production a total heating zone between the electrodes that includes a portion of the actual ION therein.


Therefore, the straddling of the ION residence zone by the present invention satisfactorily locates the electrodes so that the total heating zone produced by the electrode activation includes the ION irrespective of the actual location of the ION within the ION residence zone IRZ, thereby guaranteeing that the electrodes will always heat the ION to therapeutically beneficial temperatures.


Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a bone having an intraosseous nerve ION defining first and second sides of the bone, comprising the steps of:

  • a) inserting an energy device having an active and a return electrode into the bone,
  • b) placing the active electrode on the first side of the bone and the return electrode on the second side of the bone to define a total heating zone therebetween, and


    applying a sufficiently high frequency voltage between the active and return electrodes to generate a current therebetween to resistively beat the total heating zone sufficient to denervate the ION.


In addition, the present invention provides a very controlled total heating zone which exists substantially only between the paired electrodes. The ability of the present invention to both therapeutically heat the BVN with substantial certainty and to minimize the volume of bone tissue affected by the heating appears to be novel in light of the conventional bone-related technology.


Accordingly, the present invention is further advantageous because it allows the clinician to create a sufficiently large heating zone for therapeutically treating the ION without requiring direct access to the ION.


Thus, in preferred embodiments, the present invention is advantageous because:

  • 1) it does not require knowing the precise location of the ION,
  • 2) it does not require directly accessing the ION, and
  • 3) its controlled heating profile allows the clinician to avoid heating adjacent structures such as the healthy adjacent cancellous bone tissue, the spinal cord or opposing vertebral endplates.


Accordingly, there is also provide a method of therapeutically treating a vertebral body having a BVN defining first and second sides of the vertebral body, comprising the steps of:

  • a) determining a BVN residence zone within which the BVN likely resides, the BVN residence zone having a first side and a second side,
  • b) inserting an energy device having an active and a return electrode into the vertebral body,
  • c) placing the active electrode on the first side of the residence zone and the return electrode on the second side of the residence zone to define a total heating zone therebetween, and
  • d) applying a sufficiently high frequency voltage between the active and return electrodes to generate a current therebetween to resistively heat the total heating zone to a temperature sufficient to denervate the BVN.





DESCRIPTION OF THE FIGURES


FIGS. 1 and 2 depict the treatment of the BVN with a conventional bipolar electrode.



FIGS. 3 and 4 depict the difficulty of treating a BVN with a conventional bipolar electrode.



FIGS. 5 respectively depict top views of an electric field and a total heating zone produced within bone tissue by an embodiment of the present invention.



FIGS. 7-9 depict the treatment of the BVN with a bipolar electrode apparatus of the present invention.



FIGS. 10a and 10b disclose anterior and upper cross-sectional views of a straddled ION that extends in a plane above the electrodes but within the total heating zone.



FIG. 11 is a cross-sectional anterior view of an embodiment of the present invention in which the total heating zone has dumb-bell type resistive heating zones.



FIG. 12 depicts a top view of the treatment of the BVN with a bipolar electrode apparatus of the present invention wherein the distal ends of the probes are located substantially at the midline of the vertebral body.



FIG. 13 discloses cross-sections of components of a preferred dual probe apparatus according to the present invention.



FIG. 14 discloses an embodiment of the present invention in which a portion of the probe shaft acts as an electrode.



FIGS. 15-18 discloses four embodiments of the present invention in which at least a portion of the electrode faces thereof are disposed in a substantially parallel relation.



FIG. 19 discloses a cross-sectional view of an apparatus of the present invention in which the cannula has a bore having a distal bend and a lateral opening.



FIGS. 20a and 20b disclose cross-sectional views of an apparatus of the present invention in which the cannula has a proximal bend.



FIGS. 21a and 21b disclose cross-sectional views of an apparatus of the present invention in which the probe has a pivoted portion containing an electrode.



FIG. 22 discloses a probe of the present invention having reverse conical electrodes.



FIG. 23 discloses a probe of the present invention having a plurality of active electrodes and a corresponding plurality of return electrodes.



FIG. 24 discloses a bipolar probe of the present invention in which the return electrode has a relatively large surface area.



FIG. 25 presents a cross-sectional view of an articulated probe of the present invention having both active and return electrodes.



FIG. 26 discloses the treatment of a posterior portion of the BVN with a bipolar electrode apparatus of the present invention. FIGS. 27a-d disclose respective top, anterior, lateral and perspective views of the placement of a bipolar electrode apparatus of the present invention within a vertebral body.



FIGS. 28a and 28b show the location of thermocouples T0-T14 within the vertebral body.



FIG. 29a-c present the temperatures recorded by thermocouples T0-T14.



FIG. 30a-b present the peak temperatures recorded by thermocouples T0-T14 within the vertebral body.



FIGS. 31a-e present top views of a preferred use of the articulated probe of FIG. 25.



FIG. 32 presents a dual articulated needle embodiment of the present invention.





DETAILED DESCRIPTION OF THE INVENTION

For the purposes of the present invention, the “resistive heating zone” is the zone of bone tissue that is resistively heated due to an energy loss incurred by current travelling directly through the bone tissue. Resistive heating, “joule” heating and “near-field” heating may be used interchangeably herein. The “conductive heating zone” is the zone of bone tissue that is heated due to the conduction of heat from an adjacent resistive heating zone. The total heating zone THZ in a bone tissue includes both the resistive heating zone and the conductive heating zone. The border between the conductive and resistive heating zones is defined by the locations where the strength of the electric field is 10% of the maximum strength of the electric field between the electrodes. For the purposes of the present invention, the heating zones encompass the volume of bone tissue heated to at least 42° C. by the present invention. For the purposes of the present invention, the “first and second sides” of a vertebral body are the lateral-lateral sides intersected by the BVN.


The therapeutic treatment of the ION may be carried out in accordance with the present invention by resistive heating, conductive heating, or by hybrid heating.


In some embodiments, the therapeutic heating of the ION is provided by both resistive and conductive heating. In some embodiments thereof, as in FIG. 6, the electrodes are placed such that the ION passes through resistive heating zone IR, so that length L1 of the ION is therapeutically heated by bone tissue in the resistive heating zone IR and lengths L2 and L3 of the ION are therapeutically heated by the bone tissue in the conductive heating zone OC.


In embodiments wherein the therapeutic heating of the ION is provided substantially by both resistive and conductive heating, it is preferred that the length L1 of the ION treated by resistive heating comprise at least 25% of the total therapeutically treated length of ION, more preferably at least 50%. In many embodiments, the peak temperature in the resistive heating zone IR is between 40° C. and 60° C. greater than the peak temperature in the conductive heating zone OC. Preferably, the peak temperature in the resistive heating zone IR is no more than 15° C. greater than the peak temperature in the conductive heating zone OC, more preferably no more than 10° C., more preferably no more than 5 degrees.


Now referring to FIGS. 10a and 10b, in some embodiments, the therapeutic heating of the ION is provided essentially by the conductive heating zone OC. This may occur when the ION is in fact located substantially far from the middle of the ION residence zone IRZ. In such an instance, the electrodes are placed such that the ION passes only through the conductive heating zone, so that length L2 of the ION is therapeutically heated by bone tissue in the conductive heating zone OC.


In preferred embodiments thereof, it is desired that the separation distance SD between the ION and the resistive heating zone IR be no more than 1 cm. This is desired because the closer the ION is to the resistive heating zone, the higher the temperature experienced by the ION length L2. More preferably, the separation distance is no more than 0.5 cm, more preferably no more than 0.2 cm.


In some embodiments, as in FIG. 10, the electric field is sufficiently strong to be located substantially continuously between the two electrodes. This typically occurs when the electrodes are very close together (i.e., no more than 5 mm apart). In others, however, as in FIG. 11, the electric field is relatively weak and so resides substantially only in the vicinity of the two electrodes. In such cases, and now referring to FIG. 11, inward energy flow from the resistive heating zones IR conductively heats the intermediate area of the conductive heating zone OC1. Preferably, the peak temperature in the resistive heating zone IR is no more than 15° C. greater than the peak temperature in the intermediate conductive heating zone OC1, more preferably no more than 10° C., more preferably no more than 5° C.


In preferred embodiments, the present invention is carried out via a dual probe system. In particular, the present invention preferably comprises an energy delivery device comprising a first probe having an active electrode and a second probe having a return electrode. Now referring to FIG. 12, this dual probe embodiment allows the surgeon to approach the BVN from separate sides of the vertebral body to easily straddle the IRZ with the electrodes. With such a device, the surgeon can place the first probe 601 having an active electrode 603 on a first side of the vertebral body and the second probe 611 having a return electrode 613 on a second side of the vertebral body, and then align the paired electrodes so that their activation produces a total heating zone that straddles the IRZ and therefore the BVN therein.


Since aligning the electrodes of such an apparatus to straddle the ION merely requires advancing the probes into the vertebral body, no complicated navigation is required. The present inventors have appreciated that, even if the location of the BVN were precisely known, conventional methods of accessing the BVN require either i) the BVN to be naturally located within the vertebral body so as to intersect the axis of the pedicle (Heggeness), or require a complicated probe configuration or navigation (such as those described by Cosman). Because the dual probe approach simply requires substantially linear advance of a pair of substantially straight probes, it is much simpler and/or much more robust than the conventional methods of accessing nerves in bone. Indeed, with this embodiment of the present invention, the clinician may now desirably access the vertebral body through the pedicles with substantially straight probes and have a high confidence that their activation can therapeutically treat the BVN.


Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a vertebral body having a BVN, comprising the steps of:

  • a) providing an energy device having an active electrode having a first face and a return electrode having a second face into the vertebral body, and
  • b) placing the active electrode in the vertebral body to face a first direction,
  • c) placing the return electrode in the vertebral body to face a second direction, the first and second faces defining an angle 2δ of no more than 60 degrees, and


    applying a sufficiently high frequency voltage difference between the active and return electrodes to generate a current therebetween to produce a total heating zone to therapeutically heat the BVN.


Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a vertebral body having a BVN, comprising the steps of:

  • a) providing an energy device having an active electrode and a return electrode,
  • b) placing the active and return electrodes in the vertebral body to define an electrode axis, the axis forming an angle β of between 50 and 90 degrees with the BVN, and
  • c) applying a sufficiently high frequency voltage difference between the active and return electrodes to generate a current therebetween to produce a total heating zone to therapeutically heat the BVN.


Now referring to FIG. 13, there is provided a preferred dual probe apparatus according to the present invention comprising first 101 and second 151 cannulae, first 201 and second 251 stylets, first 301 and second 351 probes, and a power supply 401 in electrical connection with the probes. For simplicity, only a single cannula, stylet and probe will be further described. However, the skilled artisan will appreciate that preferred embodiments use two sets of such devices.


Now referring to FIG. 13, cannula 101 comprises a shaft 103 having a longitudinal bore 105 therethrough defining an inner diameter DC. Distal opening 109 of the cannula provides a working portal for the probe. It is further sized to allow the distal end of the probe to advance past the distal end 107 of the cannula. The length Lc of the cannula is sized to reach from the patient's skin to a location within the cancellous bone region of the target bone. Preferably, the cannula is made of a material selected from the group consisting of metal and polymer, and is preferably polymer. In many embodiments, the cannula is made of an insulating material in order to prevent stray current from the probe from contacting non-targeted tissue.


In some embodiments, the cannula is shaped so as to guide the probe towards the midline of the vertebral body. This inward guidance will help move the electrodes closer to the BVN. In some embodiments, at least a portion of the cannula bore is curved. In some embodiments, at least half of the length of the cannula bore is curved. In other embodiments, substantially only the distal end portion of the cannula bore is curved.


Stylet 201 comprises a shaft 203 having a longitudinal axis A and a proximal 205 and distal end 207. Disposed at the distal end of the shaft is a tip 209 adapted for boring or drilling through cortical bone. The outer diameter DO of the stylet shaft is preferably adapted to be received within the inner diameter DC of the cannula.


For the purposes of the present invention, the combination of the cannula and the stylet is referred to as a “cannulated needle”. In some embodiments, access to the vertebral body is gained by first placing the stylet in the cannula to produce a cannulated needle, piercing the skin with the cannulated needle, and advancing the cannulated needle so that the stylet tip reaches a target tissue region within the cancellous portion of the vertebral body, and then withdrawing the stylet. At this point, the cannula is conveniently located at the target tissue region to receive a probe of the present invention.


Probe 301 comprises a shaft 303 having a longitudinal axis B, a distal end portion 305 and a proximal end portion 307. Disposed near the distal end portion of the probe is first electrode 309 having a first face 331 and a connection face 333. The probe is designed so that the connection face of the first electrode is placed in electrical connection with a first lead 403 of the power supply. In this particular embodiment, the shaft has a longitudinal bore 311 extending from the proximal end portion up to at least the first electrode. Disposed within the bore is a wire 321 electrically connected at its first end 323 to the first electrode and having a second end 325 adapted to be electrically connected to a first lead of a power supply.


Therefore, in accordance with the present invention, there is provided an intraosseous nerve denervation system, comprising:

  • a) a cannula having a longitudinal bore,
  • b) a stylet having an outer diameter adapted to be received within the longitudinal bore and a distal tip adapted to penetrate cortical bone, and
  • c) a first probe comprising:
    • i) an outer diameter adapted to be received within the longitudinal bore, and
    • ii) a first electrode, and
    • iii) a lead in electrical connection with the first electrode.


In some embodiments, the outer surface of the probe is provided with depth markings so that the clinician can understand the extent to which it has penetrated the vertebral body.


In some embodiments in which a cannulated stylet is first inserted, the stylet is removed and the cannula remains in place with its distal opening residing in the target tissue while the probe is inserted into the cannula. In this embodiment, the cannula provides a secure portal for the probe, thereby insuring that the probe can enter the bone safely. This embodiment is especially preferred when the probe is made of a flexible material, or is shaped with an irregular cross-section that could undesirably catch on the bone during probe advancement into the bone.


In the FIG. 13 probe disclosed above, probe 301 has a blunt tip. In other embodiments, however, the probe carrying an electrode can be configured to possess a sharp distal tip having sufficient sharpness to penetrate cortical bone. With such a tip, the clinician can eliminate steps in the procedure that are related to either the stylet or the cannulated stylet, and thereby save time.


Now referring to FIG. 14, in some embodiments, the electrode may include a portion of the probe shaft. For example, in the case of probe 1401, the probe comprises:


a) an inner electrically conductive shaft 1403 in electrical connection with a power supply 1409, and


b) an outer insulating jacket 1405 wrapped around a portion of the shaft.


In this configuration. the placement of the jacket provides a distal uninsulated shaft portion 1407 that could be used as an electrode. Preferably, the distal uninsulated portion of the shaft has a length of between 3 mm and 8 mm, and is more preferably about 5 mm. In preferred embodiments thereof, the insulation is selected from the group consisting of polyimide tape, PTFE tape, and heat shrink tubing. Preferred thickness of the insulation range from about 0.00025 to 0.0005 inches.


In other embodiments using insulating jackets, the jacket has either a longitudinally extending slit or slot that exposes a longitudinal surface area of the underlying shaft, thereby producing either an essentially linear or an essentially planar electrode. In such embodiments, the distal end of the shaft may preferably be insulated. In other embodiments using insulating jackets, the insulated portion may comprises a proximal jacket and a distal jacket positioned to provide a space therebetween that exposes a surface area of the underlying shaft to produce the electrode. In some embodiments, the proximal and distal jacket substantially encircle the shaft to provide an annular electrode therebetween.


In some embodiments in which a cannulated stylet is used, both the stylet and the cannula are removed, and the probe is inserted into the hole created by the cannulated stylet. In this embodiment, the hole provides a large portal for the probe. This embodiment conserves the annulus of bone removed by the cannula, and so is preferred when the probe has a relatively large diameter (e.g., more than 8 mm in diameter).


In some embodiments in which a cannulated stylet is used, the cannula comprises at least one electrode In this embodiment, the cannula acts as the probe as well. With this embodiment, the clinician can eliminate steps in the procedure that are related to introducing a body into the cannula. In some embodiments, the outer surface of the cannula is provided with depth markings so that the clinician can understand the extent to which the cannula has penetrated the vertebral body.


In some embodiments in which a cannulated stylet is first inserted, the stylet comprises at least one electrode. In this embodiment, the stylet acts as the probe as well. With this embodiment, the clinician can eliminate steps in the procedure that are related to removing the stylet and introducing a body into the cannula. In some embodiments, the outer surface of the stylet is provided with depth markings so that the clinician can understand the extent to which it has penetrated the vertebral body.


In conducting initial animal experiments with a dual probe embodiment, the present inventors used a bipedicle approach as shown in FIG. 12, so that each probe approached the ION at angle δ of 45 to about 55 degrees. Since both the probes and the electrodes disposed thereon were essentially cylindrical, the inner faces 605, 615 of the electrodes produced an angle 2δ. Subsequent testing of the configuration of FIG. 12 revealed somewhat higher temperatures at the distal portion of the electrodes and somewhat lower temperatures near the proximal portions of the electrodes. Without wishing to be tied to a theory, it is believed that the shorter path between the distal regions produced a lower resistance region (as compared to more proximal inter-electrode regions) and so caused current to preferentially follow the path of the least resistance between the distal portions. Accordingly, the present inventors sought to improve upon the relatively uneven temperature profile produced by the electrode design of FIG. 12.


In accordance with the present invention the present inventors modified its electrode design to reduce the angle 2δ produces by the inner faces, so that the distance between the proximal end of the electrodes is more equal to the distance between the proximal end of the electrodes (i.e., the faces are more parallel). When the electrodes are provided in such a condition, their orientation reduces the significance of any path of least resistance, and so current flows more evenly across the face of each electrode, thereby providing even heating and greater control over the system.


Therefore, in accordance with the present invention, there is provided an intraosseous nerve denervation device, comprising:

    • a) a first probe having an active electrode and a first lead,
    • b) a second probe having a return electrode and a second lead,
    • c) means for creating first and second bores within a bone for accommodating the first and second probes,
    • d) a power supply capable of generating a voltage difference between the active and return electrodes, the supply having third and fourth leads,


wherein the first and third leads are in electrical connection, and the second and fourth leads are in electrical connection.


Preferably, the electrodes are disposed so that the angle 2δ produced by the inner faces is less than 60 degrees, more preferably no more than 30 degrees. Still more preferably, the angle is less than 1 degree. Most preferably, the inner faces are substantially parallel.


Now referring to FIG. 15, in some embodiments, substantially parallel electrodes are provided by using conical electrodes 501 that taper distally. In this FIG. 15, each cone electrode 501 has a distal end 503 having a diameter DD and a proximal end 505 having a diameter DP, wherein the distal end diameter DD is larger than the proximal end diameter DP. Preferably, the angle γ of the cone taper is substantially equal to the angle δ. In this condition, the inner faces of the conical electrodes will be essentially parallel to each other.


Therefore, in accordance with the present invention, there is provided intraosseous nerve denervation system comprising:

  • a) a first probe having a first electrode and a first lead in electrical connection with the first electrode,


    wherein the first electrode has a proximal end having a proximal diameter and a distal end having a distal diameter, and the proximal end diameter is less than the distal end diameter, and
  • b) a second probe having a first electrode and a first lead in electrical connection with the first electrode,


    wherein the first electrode has a proximal end having a proximal diameter and a distal end having a distal diameter, and the proximal end diameter is less than the distal end diameter, and


    wherein the first and second electrode are disposed so that the electrodes are parallel.


In FIG. 10, the conical shapes are frustoconical (i.e., they are portions of a cone). Frustoconical electrodes are desirable in situations where tissue charring needs to be avoided, as the relatively large diameter of the distal end of the electrode can not provide an avenue for high current density (relative to the proximal end of the electrode). Frustoconical electrodes are also desirable in situations where the probes are disposed at a relatively high angle δ, wherein the use of sharp tipped electrodes would substantially shorten the distance between the distal tips of the electrodes and thereby create an undesirable path of significantly less resistance.


In some embodiments, the frustoconical electrode is shaped so that the diameter of its distal end DD is between about 10% and 25% of the diameter of its proximal end DP. In some embodiments, the frustoconical nature of the electrode is provided by physically severing the sharp distal end of the electrode. In others, the frustoconical nature of the electrode is provided by insulating the sharp distal end of an electrode.


As noted above, when the probes are placed such that their corresponding electrodes are parallel to each other, the electric field produced by electrode activation is substantially uniform between the distal and proximal portions of the electrodes. However, as the probes are oriented at an angle from parallel, the electric field becomes strongest where the electrodes are closer together. In order to compensate for this non-uniform electric field, in some embodiments of the present invention, the distal ends of the electrodes are tapered. In this tapered state, the regions of the electrodes that are closer together (e.g., the tip) also have a smaller surface area (thereby reducing the electric field in that region), while the regions of the electrodes that are farther apart (e.g., the trunk) have a larger surface area (thereby increasing the electric field in that region). Typically, the effect is largely determined by the cone size, electrode spacing and tissue type therebetween.


In some preferred embodiments of the tapered electrode, and now referring to FIG. 16, the distal end of the electrode terminates in a sharp tip, so that the electrode has a more completely conical shape. Preferably, the conical electrode is shaped so that the diameter of its distal end is no more than 20% of the diameter of its proximal end, more preferably no more than 10%, more preferably no more than 1%. In addition to compensating for non-uniformity in the electric field, the sharp tip may also be adapted to penetrate the cortical shell of the vertebral body.


Now referring to FIG. 17, in some embodiments, current flows through an electrode having only a portion of the conical or frusto-conical shape. When electrodes of this embodiment, termed “sectored cones” face each other, their use is advantageous because they insure that current will flow the least distance, and so provide efficiency. The sectored cones of this embodiment can be produced by first manufacturing planar electrodes 511 and placing the planar electrode upon a conveniently angled probe surface 513. Alternatively, this embodiment can be produced by first manufacturing the conical electrode configuration of FIG. 15, and then masking a portion of the conical electrode with an insulating material. Unlike the embodiment of FIG. 15, this sectored cone embodiment requires careful alignment of the electrode faces and may require in vivo rotation of the electrodes to achieve the desired alignment.


Now referring to FIG. 18, in other embodiments, substantially parallel electrodes can be provided by using elbowed probes 531. The elbowed probes have a distal end 533 and a proximal end 535 meeting at an elbow 537. In some embodiments, the elbow may be produced during the manufacturing process (thereby requiring a smaller diameter probe in order to fit through the cannula). In other embodiments, the elbow is produced in vivo, such as through use of a pull-wire, a pivot or a memory metal disposed within the probe.


Now referring to FIG. 19, in some embodiments, first 551 and second 552 cannulae are each provided with a curved bore 553, 554 forming distal lateral openings 563,564 in their respective distal end portions 555, 556. When flexible probes 557, 558 containing an electrode 559,560 are passed through the curved bore, the distal end 561,562 of the probe likewise conforms to the curved bore, thereby forming an intra-probe angle ϵ determined by the proximal AP and distal AD axes of the probe. Preferably, this intra-probe angle is between 90 and 135 degrees. Preferably, the intra-probe angle is selected so that the distal axes AD of the probes exiting the cannulae form an angle of no more than 30 degrees, preferably no more than 10 degrees, more preferably form a substantially parallel relation.


Therefore, in accordance with the present invention, there is provided an intraosseous nerve denervation system, comprising:

  • a) a cannula having a longitudinal bore defining a first axis,
  • b) a stylet having an outer diameter adapted to be received within the longitudinal bore and a distal tip adapted to penetrate cortical bone, and
  • c) a first probe comprising:
  • d) an outer diameter adapted to be received within the longitudinal bore, and
    • i) a first electrode, and
    • ii) a lead in electrical connection with the first electrode.


Now referring to FIGS. 20a and 20b, in some embodiments, first 701 and second 751 cannulae are each provided with a curved bore 703, 753 in their respective distal portions 705, 755, wherein each bore has a proximal lateral opening 707,757. The apparatus further comprises first and second probes 711, 761, each containing an electrode 713,763. In some embodiments, the probe may sit in a distal region of the bore (as in FIG. 20a) during advance of the cannula. Once the target tissue region is reached, then probes are moved proximally (by, for example, a pull wire not shown) and exit the proximal lateral openings so that the inner faces 715, 765 of the electrodes face other.


Therefore, in accordance with the present invention, there is provided an intraosseous nerve denervation system, comprising:

  • a) a cannula having a longitudinal bore defining a first axis,
  • b) a stylet having an outer diameter adapted to be received within the longitudinal bore and a distal tip adapted to penetrate cortical bone, and
  • c) a first probe comprising:
    • i) an outer diameter adapted to be received within the longitudinal bore, and
    • ii) a first electrode, and
    • iii) a lead in electrical connection with the first electrode.


Now referring to FIGS. 21a and 21b, in some embodiments, at least one probe 801 comprises i) a distal portion 803 having an electrode 805 and ii) a proximal portion 807, the distal portion being pivotally attached to the proximal portion by pivot 809. In some embodiments, two probes having such pivotally attached electrodes are introduced through the cannulae in a first linear mode (shown in FIG. 21a) to produce an angle θ between the electrodes. Next, the respective pivots are actuated (by for example, a pull wire—not shown) to produce the angled configuration shown in FIG. 21b which reduces the angle θ between the electrodes. Preferably, the pivoting brings the electrodes into a substantially parallel relation.


Therefore, in accordance with the present invention, there is provided intraosseous nerve denervation system comprising:

  • a) a first probe having:
    • i) a distal portion having a first electrode,
    • ii) a proximal portion comprising a first lead in electrical connection with the first electrode, and
    • iii) a pivot pivotally connecting the proximal and distal portions of the probe.


In some embodiments, relatively even heating is provided by providing current density gradients. Now referring to FIG. 22, in some embodiments, first 821 and second 831 probes have first 823 and second 833 electrodes having a reverse conical shape. In particular, each electrode has a relatively thick distal portion 827, 837 and a relatively thin proximal portion 825, 835. When this probe is activated, it is believed that the current density of this electrode will vary axially, with a relatively high current density present at the proximal portion of each electrode (due to the smaller surface area) and a relatively low current density present at the distal portion of the electrode (due to the larger surface area). This current density gradient should provide a more even heating zone when the electrodes themselves are oriented at a significant angle, as the preference for tip heating (caused by the angled orientation of the electrodes) is substantially balanced by the higher current density at the proximal portions of the electrodes.


Therefore, in accordance with the present invention, there is provided an intraosseous nerve denervation system comprising:




  • a) a first probe having a first electrode and a first lead in electrical connection with the first electrode,


    wherein the first electrode has a proximal end having a proximal diameter and a distal end having a distal diameter, and


    wherein the proximal end diameter is less than the distal end diameter.



Current density gradients can also be produced by providing a plurality of electrodes on each probe. Now referring to FIG. 23, in some embodiments, first and second electrodes each have a plurality of electrodes. In particular, first probe 851 has first 853, second 854 and third 855 active electrodes, while second probe 861 has first 863, second 864 and third 865 return electrodes. The voltage across the probes can be selected so that there is increasing voltage (and therefore current) across the more widely spaced electrodes (i.e., V855-865<V854-864<V853-863). In some embodiments, the probes of FIG. 23 are driven by multiple voltage sources (i.e., a first voltage source for providing voltage between first active electrode 853 and first return electrode 863, etc.).


Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a vertebral body having a BVN, comprising the steps of:

  • a) providing a first energy device having distal and proximal active electrodes,
  • b) providing a second energy device having distal and proximal return electrodes,
  • c) placing the first and second energy devices in the vertebral body to define a first distance between the distal active electrode and the distal return electrode, and a second distance between the proximal active electrode and the proximal return electrode, wherein the first distance is less than the second distance,
  • d) applying a first high frequency voltage between the distal active and distal return electrodes, and
    • applying a second high frequency voltage between the proximal active and proximal return electrodes, wherein the first high frequency voltage is less than the second high frequency voltage.


Because multiple voltage sources may add complexity to the device, in other embodiments, the differences in voltage may be provided by a single voltage source by using a poorly conductive electrode. In particular, in some embodiments thereof, the probe comprises an electrically conductive probe shaft and a plurality of spaced apart insulating jackets wherein the spacing produces the electrodes of FIG. 23. In this jacketed embodiment, the probe shaft can be made of a material that is a relatively poor electrical conductor (such as tantalum) so that, when a single driving force is applied between the jacketed probes, the voltage is highest at the proximal electrode 853, but loss due to the poor conductance produces a substantially lower voltage at distal electrode 855. This jacketed embodiment eliminates the need for multiple voltage sources.


In another dual probe approach, in some embodiments, and now referring to FIG. 24, there is provided an apparatus having first probe 871 having an active electrode 873, and a second 881 probe having a return electrode 883, wherein the ratio of the surface area of the active electrode to the surface area of the return electrode is very high,. i.e., at least 2:1 (more preferably at least 5:1). In this condition, the current density will be very high at the active electrode and very low at the return electrode, so that the total heating zone THZ will occur essentially only around the active electrode. Since this device heats essentially only at the active electrode, this device substantially mimics the heating profile of a monopolar electrode, but provides the desirable safety feature of locally directing the current to the return electrode.


Therefore, in accordance with the present invention, there is provided an intraosseous nerve denervation system comprising:

  • a) a first probe having:
    • i) an active electrode having a first surface area, and
    • ii) a first lead in electrical connection with the first electrode,
  • b) a second probe having:
    • i) a return electrode having a first surface area, and
    • ii) a second lead in electrical connection with the second electrode,


      wherein the first surface area is at least two times greater than the second surface area, and,


      means for creating first and second bores within a bone for accommodating the first and second probes.


Although the dual probe approach has many benefits, in other embodiments of the present invention, an articulated probe having both active and return electrodes may be used in accordance with the present invention.


Now referring to FIG. 25, there is provided a preferred articulated device according to the present invention. In preferred embodiments, this device 900 comprises a fixed probe 901 and a pivotable probe 951.


Fixed probe 901 comprises a shaft 903 having a longitudinal axis and a distal end portion 905 comprising sharpened distal tip 906 and a proximal end portion 907. Disposed near the distal end portion of the probe is first electrode 909. The fixed probe is designed so that the first electrode is placed in electrical connection with a first lead of a power supply. In this particular embodiment, the shaft has a longitudinal bore 911 running from the proximal end portion up to at least the first electrode. Disposed within the bore is a first wire (not shown) electrically connected at its first end to the first electrode and having a second end adapted to be electrically connected to a first lead of a power supply (not shown). The fixed probe also comprises a recess 927 forming a lateral opening in the shaft and designed to house the pivotable probe when in its undeployed mode.


Pivotable probe 951 comprises a shaft 953 having a longitudinal axis, a distal end portion 955, and a proximal end portion 957 pivotally attached to the fixed probe by pivot 961. The pivot allows the pivoting probe to pivot about the fixed probe. Disposed near the distal end portion of the pivotable probe is second electrode 963. The probe is designed so that the second electrode is placed in electrical connection with a second lead of the power supply.


The pivotable probe has an undeployed mode and a deployed mode. In the un-deployed mode, the pivotable probe is seated within the recess of the fixed probe so that the axis of its shaft is essentially in line with the axis of the fixed probe shaft. In this state, the pivotable probe essentially hides within the fixed probe. In the deployed mode, the pivotable probe extends at a significant angle from the fixed probe so that the axis of its shaft forms an angle of at least 10 degrees with the axis of the fixed probe shaft.


In some embodiments, a pusher rod is used to deploy the pivotable probe. Pusher rod 975 comprises a proximal handle (not shown) for gripping and a distal end portion 977 having a shape for accessing the bore of the fixed probe. Distal end portion has a tip 981 having a shape which, when advanced distally, can push the distal end portion of the pivotable probe laterally out of the recess.


Therefore, in accordance with the present invention, there is provided a device for denervating an ION in a bone, comprising:

    • a) a fixed probe having a first electrode thereon in electrical connection with the powder supply, and
    • b) a pivotable probe comprising a second electrode having a proximal portion pivotally engaged to the fixed probe.


In some embodiments, the pivotable device has both an active and a return electrode, and the device is introduced through a single pedicle. The location of these electrodes may vary depending upon the use of the pivotable device. For example, when the active electrode is located on the pivotable probe, the return electrode may be positioned in a location selected from the group consisting of:


a) a location on the fixed probe distal of the pivot (as in FIG. 25);


b) a location on the fixed probe proximal of the pivot;


c) a location on the pivotable probe located nearer the pivot; and


d) a location on the pusher rod.


In other embodiments, the locations of the active and return electrodes are reversed from those described above.


In general, it is desirable to operate the present invention in a manner that produces a peak temperature in the target tissue of between about 80° C. and 95° C. When the peak temperature is below 80° C., the off-peak temperatures may quickly fall below about 45° C. When the peak temperature is above about 95° C., the bone tissue exposed to that peak temperature may experience necrosis and produce charring. This charring reduces the electrical conductivity of the charred tissue, thereby making it more difficult to pass RF current through the target tissue beyond the char and to resistively heat the target tissue beyond the char. In some embodiments, the peak temperature is preferably between 86° C. and 94° C.


It is desirable to heat the volume of target tissue to a minimum temperature of at least 42° C. When the tissue experiences a temperature above 42° C., nerves within the target tissue may be desirably damaged. However, it is believed that denervation is a function of the total quantum of energy delivered to the target tissue, i.e., both exposure temperature and exposure time determine the total dose of energy delivered. Accordingly, if the temperature of the target tissue reaches only about 42° C., then it is believed that the exposure time of the volume of target tissue to that temperature should be at least about 30 minutes and preferably at least 60 minutes in order to deliver the dose of energy believed necessary to denervate the nerves within the target tissue.


Preferably, it is desirable to heat the volume of target tissue to a minimum temperature of at least 50° C. If the temperature of the target tissue reaches about 50° C., then it is believed that the exposure time of the volume of target tissue to that temperature need only be in the range of about 2 minutes to 10 minutes to achieve denervation.


More preferably, it is desirable to heat the volume of target tissue to a minimum temperature of at least 60° C. If the temperature of the target tissue reaches about 60° C., then it is believed that the exposure time of the volume of target tissue to that temperature need only be in the range of about 0.01 minutes to 1.5 minutes to achieve denervation, preferably 0.1 minutes to 0.25 minutes.


Typically, the period of time that an ION is exposed to therapeutic temperatures is in general related to the length of time in which the electrodes are activated. However, since it has been observed that the total heating zone remains relatively hot even after power has been turned off (and the electric field eliminated), the exposure time can include a period of time in which current is not running through the electrodes.


In general, the farther apart the electrodes, the greater the likelihood that the ION will be contained within the total heating zone. Therefore, in some embodiments, the electrodes are placed at least 5 mm apart, more preferably at least 10 mm apart. However, if the electrodes are spaced too far apart, the electric field takes on an undesirably extreme dumbbell shape. Therefore, in many preferred embodiments, the electrodes are placed apart a distance of between 5 mm and 25 mm, more preferably between 5 mm and 15 mm, more preferably between 10 mm and 15 mm.


In some embodiments, it is desirable to heat the target tissue so that at least about 1 cc of bone tissue experiences the minimum temperature. This volume corresponds to a sphere having a radius of about 0.6 cm. Alternatively stated, it is desirable to heat the target tissue so the minimum temperature is achieved by every portion of the bone within 0.6 cm of the point experiencing the peak temperature.


More preferably, it is desirable to heat the target tissue so that at least about 3 cc of bone experiences the minimum temperature. This volume corresponds to a sphere having a radius of about 1 cm.


In one preferred embodiment, the present invention provides a steady-state heated zone having a peak temperature of between 80° C. and 95° C. (and preferably between 86° C. and 94° C.), and heats at least 1 cc of bone (and preferably at least 3 cc of bone) to a temperature of at least 50° C. (and preferably 60° C.).


Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a vertebral body having a BVN, comprising the steps of:

  • a) providing an energy device having an active and a return electrode,
  • a) inserting the active electrode into the vertebral body,
  • b) inserting the return electrode into the vertebral body, and
  • c) applying a sufficiently high frequency voltage difference between the active and return electrodes to generate a current therebetween to produce a total heating zone having a diameter of at least 0.5 cm and a steady state temperature of at least 50° C.


As noted above, a peak temperature below about 100° C. is desirable in order to prevent charring of the adjacent tissue, steam formation and tissue popping. In some embodiments, this is accomplished by providing the power supply with a feedback means that allows the peak temperature within the heating zone to be maintained at a desired target temperature, such as 90° C. In some embodiments, between about 24 watts and 30 watts of power is first supplied to the device in order to rapidly heat the relatively cool bone, with maximum amperage being obtained within about 10-15 seconds. As the bone is further heated to the target temperature, the feedback means gradually reduces the power input to the device to between about 6-10 watts.


If the active electrode has no active cooling means, it may become be subject to conductive heating by the heated tissue, and the resultant increased temperature in the electrode may adversely affect performance by charring the adjacent bone tissue. Accordingly, in some embodiments, a cool tip active electrode may be employed. The cooled electrode helps maintain the temperature of the electrode at a desired temperature. Cooled tip active electrodes are known in the art. Alternatively, the power supply may be designed to provided a pulsed energy input. It has been found that pulsing the current favorably allows heat to dissipate from the electrode tip, and so the active electrode stays relatively cooler.


The following section relates to the general structure of preferred energy devices in accordance with the present invention:


The apparatus according to the present invention comprises an electro surgical probe having a shaft with a proximal end, a distal end, and at least one active electrode at or near the distal end. A connector is provided at or near the proximal end of the shaft for electrically coupling the active electrode to a high frequency voltage source. In some embodiments, a return electrode coupled to the voltage source is spaced a sufficient distance from the active electrode to substantially avoid or minimize current shorting therebetween. The return electrode may be provided integral with the shaft of the probe or it may be separate from the shaft


In preferred embodiments, the electrosurgical probe or catheter will comprise a shaft or a handpiece having a proximal end and a distal end which supports one or more electrode terminal(s). The shaft or handpiece may assume a wide variety of configurations, with the primary purpose being to mechanically support the active electrode and permit the treating physician to manipulate the electrode from a proximal end of the shaft. The shaft may be rigid or flexible, with flexible shafts optionally being combined with a generally rigid external tube for mechanical support. Flexible shafts may be combined with pull wires, shape memory actuators, and other known mechanisms for effecting selective deflection of the distal end of the shaft to facilitate positioning of the electrode array. The shaft will usually include a plurality of wires or other conductive elements running axially therethrough to permit connection of the electrode array to a connector at the proximal end of the shaft.


Preferably, the shaft may be a rigid needle that is introduced through a percutaneous penetration in the patient. However, for endoscopic procedures within the spine, the shaft will have a suitable diameter and length to allow the surgeon to reach the target site (e.g., a disc) by delivering the shaft through the thoracic cavity, the abdomen or the like. Thus, the shaft will usually have a length in the range of about 5.0 to 30.0 cm, and a diameter in the range of about 0.2 mm to about 10 mm. In any of these embodiments, the shaft may also be introduced through rigid or flexible endoscopes.


The probe will include one or more active electrode(s) for applying electrical energy to tissues within the spine. The probe may include one or more return electrode(s), or the return electrode may be positioned on the patient's back, as a dispersive pad. In either embodiment, sufficient electrical energy is applied through the probe to the active electrode(s) to either necrose the blood supply or nerves within the vertebral body.


The electrosurgical instrument may also be a catheter that is delivered percutaneously and/or endoluminally into the patient by insertion through a conventional or specialized guide catheter, or the invention may include a catheter having an active electrode or electrode array integral with its distal end. The catheter shaft may be rigid or flexible, with flexible shafts optionally being combined with a generally rigid external tube for mechanical support. Flexible shafts may be combined with pull wires, shape memory actuators, and other known mechanisms for effecting selective deflection of the distal end of the shaft to facilitate positioning of the electrode or electrode array. The catheter shaft will usually include a plurality of wires or other conductive elements running axially therethrough to permit connection of the electrode or electrode array and the return electrode to a connector at the proximal end of the catheter shaft. The catheter shaft may include a guide wire for guiding the catheter to the target site, or the catheter may comprise a steerable guide catheter. The catheter may also include a substantially rigid distal end portion to increase the torque control of the distal end portion as the catheter is advanced further into the patient's body. Specific deployment means will be described in detail in connection with the figures hereinafter.


In some embodiments, the electrically conductive wires may run freely inside the catheter bore in an unconstrained made, or within multiple lumens within the catheter bore.


The tip region of the instrument may comprise many independent electrode terminals designed to deliver electrical energy in the vicinity of the tip. The selective application of electrical energy is achieved by connecting each individual electrode terminal and the return electrode to a power source having independently controlled or current limited channels. The return electrode(s) may comprise a single tubular member of conductive material proximal to the electrode array. Alternatively, the instrument may comprise an array of return electrodes at the distal tip of the instrument (together with the active electrodes) to maintain the electric current at the tip. The application of high frequency voltage between the return electrode(s) and the electrode array results in the generation of high electric field intensities at the distal tips of the electrode terminals with conduction of high frequency current from each individual electrode terminal to the return electrode. The current flow from each individual electrode terminal to the return electrode(s) is controlled by either active or passive means, or a combination thereof, to deliver electrical energy to the surrounding conductive fluid while minimizing energy delivery to surrounding (non-target) tissue.


Temperature probes associated with the apparatus may preferably be disposed on or within the electrode carrier; between the electrodes (preferred in bipolar embodiments); or within the electrodes (preferred for monopolar embodiments). In some embodiments wherein the electrodes are placed on either side of the ION, a temperature probe is disposed between the electrodes or in the electrodes. In alternate embodiments, the deployable portion of the temperature probe comprises a memory metal.


The electrode terminal(s) are preferably supported within or by an inorganic insulating support positioned near the distal end of the instrument shaft. The return electrode may be located on the instrument shaft, on another instrument or on the external surface of the patient (i.e., a dispersive pad). The close proximity of the dual needle design to the intraosseus nerve makes a bipolar design more preferable because this minimizes the current flow through non-target tissue and surrounding nerves. Accordingly, the return electrode is preferably either integrated with the instrument body, or another instrument located in close proximity thereto. The proximal end of the instrument(s) will include the appropriate electrical connections for coupling the return electrode(s) and the electrode terminal(s) to a high frequency power supply, such as an electrosurgical generator.


In some embodiments, the active electrode(s) have an active portion or surface with surface geometries shaped to promote the electric field intensity and associated current density along the leading edges of the electrodes. Suitable surface geometries may be obtained by creating electrode shapes that include preferential sharp edges, or by creating asperities or other surface roughness on the active surface(s) of the electrodes. Electrode shapes according to the present invention can include the use of formed wire (e.g., by drawing round wire through a shaping die) to form electrodes with a variety of cross-sectional shapes, such as square, rectangular, L or V shaped, or the like. Electrode edges may also be created by removing a portion of the elongate metal electrode to reshape the cross-section. For example, material can be ground along the length of a round or hollow wire electrode to form D or C shaped wires, respectively, with edges facing in the cutting direction. Alternatively, material can be removed at closely spaced intervals along the electrode length to form transverse grooves, slots, threads or the like along the electrodes. In other embodiments, the probe can be sectored so that a given circumference comprises an electrode region and an inactive region. In some embodiments, the inactive region is masked.


The return electrode is typically spaced proximally from the active electrode(s) a suitable. In most of the embodiments described herein, the distal edge of the exposed surface of the return electrode is spaced about 5 to 25 mm from the proximal edge of the exposed surface of the active electrode(s), in dual needle insertions. Of course, this distance may vary with different voltage ranges, the electrode geometry and depend on the proximity of tissue structures to active and return electrodes. The return electrode will typically have an exposed length in the range of about 1 to 20 mm.


The application of a high frequency voltage between the return electrode(s) and the electrode terminal(s) for appropriate time intervals effects modifying the target tissue.


The present invention may use a single active electrode terminal or an array of electrode terminals spaced around the distal surface of a catheter or probe. In the latter embodiment, the electrode array usually includes a plurality of independently current-limited and/or power-controlled electrode terminals to apply electrical energy selectively to the target tissue while limiting the unwanted application of electrical energy to the surrounding tissue and environment resulting from power dissipation into surrounding electrically conductive fluids, such as blood, normal saline, and the like. The electrode terminals may be independently current-limited by isolating the terminals from each other and connecting each terminal to a separate power source that is isolated from the other electrode terminals. Alternatively, the electrode terminals may be connected to each other at either the proximal or distal ends of the catheter to form a single wire that couples to a power source.


In one configuration, each individual electrode terminal in the electrode array is electrically insulated from all other electrode terminals in the array within said instrument and is connected to a power source which is isolated from each of the other electrode terminals in the array or to circuitry which limits or interrupts current flow to the electrode terminal when low resistivity material (e.g., blood) causes a lower impedance path between the return electrode and the individual electrode terminal. The isolated power sources for each individual electrode terminal may be separate power supply circuits having internal impedance characteristics which limit power to the associated electrode terminal when a low impedance return path is encountered. By way of example, the isolated power source may be a user selectable constant current source. In this embodiment, lower impedance paths will automatically result in lower resistive heating levels since the heating is proportional to the square of the operating current times the impedance. Alternatively, a single power source may be connected to each of the electrode terminals through independently actuatable switches, or by independent current limiting elements, such as inductors, capacitors, resistors and/or combinations thereof. The current limiting elements may be provided in the instrument, connectors, cable, controller or along the conductive path from the controller to the distal tip of the instrument. Alternatively, the resistance and/or capacitance may occur on the surface of the active electrode terminal(s) due to oxide layers which form selected electrode terminals (e.g., titanium or a resistive coating on the surface of metal, such as platinum).


In a preferred aspect of the invention, the active electrode comprises an electrode array having a plurality of electrically isolated electrode terminals disposed over a contact surface, which may be a planar or non-planar surface and which may be located at the distal tip or over a lateral surface of the shaft, or over both the tip and lateral surface(s). The electrode array will include at least two and preferably more electrode terminals, and may further comprise a temperature sensor. In a preferred aspect, each electrode terminal will be connected to the proximal connector by an electrically isolated conductor disposed within the shaft. The conductors permit independent electrical coupling of the electrode terminals to a high frequency power supply and control system with optional temperature monitor for operation of the probe. The control system preferably incorporate active and/or passive current limiting structures, which are designed to limit current flow when the associated electrode terminal is in contact with a low resistance return path back to the return electrode.


The use of such electrode arrays in electrosurgical procedures is particularly advantageous as it has been found to limit the depth of tissue necrosis without substantially reducing power delivery. The voltage applied to each electrode terminal causes electrical energy to be imparted to any body structure which is contacted by, or comes into close proximity with, the electrode terminal, where a current flow through all low electrical impedance paths is preferably but not necessarily limited. Since some of the needles are hollow, a conductive fluid could be added through the needle and into the bone structure for the purposes of lowering the electrical impedance and fill the spaces in the cancellous bone to make them better conductors to the needle.


It should be clearly understood that the invention is not limited to electrically isolated electrode terminals, or even to a plurality of electrode terminals. For example, the array of active electrode terminals may be connected to a single lead that extends through the catheter shaft to a power source of high frequency current. Alternatively, the instrument may incorporate a single electrode that extends directly through the catheter shaft or is connected to a single lead that extends to the power source. The active electrode(s) may have ball shapes, twizzle shapes, spring shapes, twisted metal shapes, cone shapes, annular or solid tube shapes or the like. Alternatively, the electrode(s) may comprise a plurality of filaments, rigid or flexible brush electrode(s), side-effect brush electrode(s) on a lateral surface of the shaft, coiled electrode(s) or the like.


The voltage difference applied between the return electrode(s) and the electrode terminal(s) will be at high or radio frequency, typically between about 50 kHz and 20 MHz, usually being between about 100 kHz and 2.5 MHz, preferably being between about 400 kHz and 1000 kHz, often less than 600 kHz, and often between about 500 kHz and 600 kHz. The RMS (root mean square) voltage applied will usually be in the range from about 5 volts to 1000 volts, preferably being in the range from about 10 volts to 200 volts, often between about 20 to 100 volts depending on the electrode terminal size, the operating frequency and the operation mode of the particular procedure. Lower peak-to-peak voltages will be used for tissue coagulation, thermal heating of tissue, or collagen contraction and will typically be in the range from 50 to 1500, preferably 100 to 1000 and more preferably 120 to 400 volts peak-to-peak. As discussed above, the voltage is usually delivered continuously with a sufficiently high frequency (e.g., on the order of 50 kHz to 20 MHz) (as compared with e.g., lasers claiming small depths of necrosis, which are generally pulsed about 10 to 20 Hz). In addition, the sine wave duty cycle (i.e., cumulative time in any one-second interval that energy is applied) is preferably on the order of about 100% for the present invention, as compared with pulsed lasers which typically have a duty cycle of about 0.0001%.


The preferred power source of the present invention delivers a high frequency current selectable to generate average power levels ranging from several milliwatts to tens of watts per electrode, depending on the volume of target tissue being heated, and/or the maximum allowed temperature selected for the instrument tip. The power source allows the user to select the power level according to the specific requirements of a particular procedure.


The power source may be current limited or otherwise controlled so that undesired heating of the target tissue or surrounding (non-target) tissue does not occur. In a presently preferred embodiment of the present invention, current limiting inductors are placed in series with each independent electrode terminal, where the inductance of the inductor is in the range of 10 uH to 50,000 uH, depending on the electrical properties of the target tissue, the desired tissue heating rate and the operating frequency. Alternatively, capacitor-inductor (LC) circuit structures may be employed, as described previously in U.S. Pat. No. 5,697,909. Additionally, current limiting resistors may be selected. Preferably, microprocessors are employed to monitor the measured current and control the output to limit the current.


The area of the tissue treatment surface can vary widely, and the tissue treatment surface can assume a variety of geometries, with particular areas and geometries being selected for specific applications. The geometries can be planar, concave, convex, hemispherical, conical, linear “in-line” array or virtually any other regular or irregular shape. Most commonly, the active electrode(s) or electrode terminal(s) will be formed at the distal tip of the electro surgical instrument shaft, frequently being planar, disk-shaped, or hemispherical surfaces for use in reshaping procedures or being linear arrays for use in cutting. Alternatively or additionally, the active electrode(s) may be formed on lateral surfaces of the electrosurgical instrument shaft (e.g., in the manner of a spatula), facilitating access to certain body structures in endoscopic procedures.


The devices of the present invention may be suitably used for insertion into any hard tissue in the human body. In some embodiments, the hard tissue is bone. In other embodiments, the hard tissue is cartilage. In preferred embodiments when bone is selected as the tissue of choice, the bone is a vertebral body. Preferably, the present invention is adapted to puncture the hard cortical shell of the bone and penetrate at least a portion of the underlying cancellous bone. In some embodiments, the probe advances into the bone to a distance of at least ⅓ of the cross-section of the bone defined by the advance of the probe. In some embodiments, the present invention is practiced in vertebral bodies substantially free of tumors. In others, the present invention is practiced in vertebral bodies having tumors.


Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a healthy vertebral body having a BVN, comprising the steps of:

  • a) providing an energy device having an active and a return electrode,
  • b) inserting the active electrode into the healthy vertebral body,
  • c) inserting the return electrode into the healthy vertebral body,
  • d) placing the active electrode on a first side of the healthy vertebral body and the return electrode on a second side of the healthy vertebral body, and


applying a sufficiently high frequency voltage difference between the active and return electrodes to generate a current therebetween to produce a total heating zone to therapeutically heat the BVN.


In some embodiments using two separate probes, the device of the present invention enters the hard tissue (preferably bone, more preferably the vertebral body) through two access points. In preferred embodiments, the pair of separate probes is adapted to denervate the BVN and enter through separate pedicles transpedicularly. In other embodiments, the pair of separate probes each enters the vertebral body extrapedicularly. In other embodiments, a first of the pair of separate probes enters the vertebral body extrapedicularly and the second enters the vertebral body transpedicularly. In embodiments using a single articulated device, the device enters via a single pedicle.


Now referring to FIG. 26, in some embodiments, the target region of the BVN is located within the cancellous portion of the bone (i.e., to the interior of the outer cortical bone region), and proximal to the junction J of the BVN having a plurality of branches. Treatment in this region is advantageous because only a single portion of the BVN need be effectively treated to denervate the entire system. In contrast, treatment of the BVN in locations more downstream than the junction require the denervation of each branch.


Therefore, in accordance with the present invention, there is provided a method of therapeutically treating a vertebral body having an outer cortical bone region and an inner cancellous bone region, and a BVN having a trunk extending from the outer cortical bone region into the inner cancellous region and a branches extending from the trunk to define a BVN junction, comprising the steps of:

  • a) inserting an energy device into the vertebral body, and
  • b) exclusively depositing energy within the inner cancellous bone region of the vertebral body between, but exclusive of the BVN junction and the outer cortical bone region, to denervate the BVN.


Typically, treatment in accordance with this embodiment can be effectuated by placing the electrodes in the region of the vertebral body located between 60% (point A) and 90% (point B) of the distance between the anterior and posterior ends of the vertebral body, as shown in FIG. 26.


EXAMPLE I

This prophetic example describes a preferred dual probe embodiment of the present invention.


First, after induction of an appropriate amount of a local anesthesia, the human patient is placed in a prone position on the table. The C-arm of an X-ray apparatus is positioned so that the X-rays are perpendicular to the axis of the spine. This positioning provides a lateral view of the vertebral body, thereby allowing the surgeon to view the access of the apparatus into the vertebral body.


Next, a cannulated stylet comprising an inner stylet and an outer cannula are inserted into the skin above each of the respective pedicles so that the distal tip of each stylet is in close proximity to the respective pedicle.


Next, the probe is advanced interiorly into the body so that the stylet tips bores through the skin, into and through the pedicle, and then into the vertebral body. The stylet is advanced until the tips reach the anterior-posterior midline of the vertebral body.


Next, the stylet is withdrawn and probe is inserted into the cannula and advanced until the first and second electrodes thereof each reach the midline of the vertebral body. The location of the two probes is shown from various perspectives in FIG. 27a-d.


Next, the power supply is activated to provide a voltage between the first and second electrodes. The amount of voltage across the electrodes is sufficient to produce an electric current between the first and second electrodes. This current provides resistive heating of the tissue disposed between the electrodes in an amount sufficient to raise the temperature of the local portion of the BVN to at least 45° C., thereby denervating the BVN.


EXAMPLE II

This example describes the efficacy of heating a large zone of a vertebral body with a bipolar energy device.


A pair of probes were inserted into a vertebral body of a porcine cadaver so that the tips of the electrodes were located substantially at the midline and separated by about 4 mm. Each electrode had a cylindrical shape, a length of about 20 mm, and a diameter of about 1.65 mm2 (16 gauge) to produce a surface area of about 100 mm2.


Next, and now referring to FIGS. 28a and 28b, thermocouples 0-14 were placed within the vertebral body at the 15 locations. Thermocouples 0-4 were placed halfway between the electrode tips and were separated by a distance of 2 mm. Thermocouples 5-9 were placed about at the midpoint between the probe tips, and were vertically separated by a distance of 2 mm Thermocouples 10-14 were placed along the distal portion of the probe and were separated by a distance of 5 mm.


Next, about 57 volts of energy was applied across the electrodes, and the temperature rise in the tissue was recorded at the thermocouple sites. These temperatures are provided in FIGS. 29a-c. In general, the temperature at each site rose somewhat steadily from about 22° C. to its peak temperature in about 200-300 seconds, whereupon feedback controls maintained the peak temperatures.



FIGS. 30a and 30b provide the peak temperatures recorded by each thermocouple. Analysis of the results in FIGS. 17a and 17b reveals that peak temperatures of between about 80° C. and 95° C. were able to be sustained over substantial distances. In particular, a temperature of 79.4 degrees was reached about 10 mm along the electrode (T11); temperatures of between 76.7 and 80.3° C. were reached at a depth of about 4 mm within the tissue (T5 and T9); and a temperature of 76.8° C. was reached about 10 mm along the electrode (T3).


The positive results provided by this example has great significance to the problem of therapeutically heating IONs, and the BVN in particular. In particular, the results of thermocouples T5-9 indicates that if an ION were located along the z-axis within 2 mm of the presumed center of the IRZ, then the ION could be sufficiently treated to at least 80° C. Similarly, the results of thermocouples T0-4 indicates that as much as a 16 mm length of ION could be sufficiently treated to at least 80° C. Lastly, the results of thermocouples. T 10-14 indicate that the ION could be off-center laterally in the IRZ by as much as 2 mm and at least about 10 mm of its length could be sufficiently treated to at least 80 C.


EXAMPLE III

This embodiment describes a preferred articulated probe embodiment of the present invention.


The initial steps described above in Example I are carried out so that the articulated probe is poised on the patient's skin and held in place by a ratchet type gun. See FIG. 31a.


Next, the distal end of the articulated probe is inserted into the skin above a pedicle so that the distal end of the fixed probe is in close proximity, to the pedicle.


Now referring to FIG. 31b, the probe is advanced interiorly into the body so that the distal tip bores through the skin, into and through the pedicle, and then into the vertebral body. The distal tip is advanced until it reaches about 30% beyond the anterior-posterior midline of the vertebral body.


Now referring to FIG. 31c, the distal end of the pusher rod is inserted into the bore of the fixed probe and advanced until the angled portion of the pusher rod contacts the angled portion of the pivotable probe, thereby nudging the pivotable probe out of the recess. The pivotable probe is now in a partially deployed mode.


Now referring to FIG. 31d, the apparatus is slightly withdrawn from the body. As this occurs, the bone disposed between the pivotable and fixed probes prevents the pivotable probe from withdrawing along with the fixed probe, but rather forces open the pivoting means, thereby bringing the axis of the pivotable probe to a position substantially normal to the axis of the fixed probe. The pivotable probe is now in extended mode.


Next, the power supply is activated to provide a voltage between the first and second electrodes. The amount of voltage across the electrodes is sufficient to produce an electric current between the first and second electrodes. This current provides resistive heating of the tissue disposed between the electrodes in an amount sufficient to raise the temperature of the local portion of the BVN to at least 45° C., thereby denervating the BVN.


Next, the fixed probe is pushed forward to bring the pivotable probe back into the recess.


Now referring to FIGS. 31e, the probe is removed from the body.


EXAMPLE IV

Now referring to FIG. 32, there is provided a dual articulated needle embodiment of the present invention, wherein the articulated needles are each advanced down the pedicles of the vertebral body, and each of the pivotable probes are deployed at an angle of less than 90 degrees, so that the electrodes thereon align themselves in an essentially parallel relationship. Because the electric field produced by this embodiment is relatviely even between the electrodes, the resulting total heating zone is also desirably homogeneous. Because the electrodes deploy in the central posterior portion of the vertebral body, the BVN is desirably denervated near its trunk.

Claims
  • 1. A method of therapeutically treating a vertebral body having an outer cortical bone region, an inner cancellous bone region, and a basivertebral nerve BVN, comprising the steps of: providing a probe configured to deploy an energy device having an electrode;the probe comprising a longitudinal bore extending from a proximal end of the probe toward a distal end of the probe;the probe comprising a recess in communication with said bore, said recess forming a lateral opening at or near the distal end of the probe;the probe further comprising a pivotable member;the pivotable member having a fixed end pivotably secured to the probe at a distal location within the recess of the probe, and a free end configured to be seated in said recess;wherein the pivotable member comprises an undeployed mode where the free end extends proximally from the fixed end within said recess, and a deployed mode where the free end is configured to pivot about said fixed end and extend outward from said probe;articulating the pivotable member from the undeployed mode to the deployed mode to facilitate delivery of the energy device along a path associated with the free end of the pivotable member into the cancellous bone region of the vertebral body; andapplying a sufficiently high frequency voltage to the electrode to heat the BVN.
  • 2. A method as recited in claim 1, the BVN having a trunk extending from the outer cortical bone region and into the inner cancellous bone region and branches extending from the trunk to define a BVN junction, wherein therapeutically heating the BVN comprises: depositing therapeutic energy within the inner cancellous bone region of the vertebral body.
  • 3. The method of claim 2, wherein the therapeutic energy is deposited in a region of the vertebral body located between 60% and 90% of the distance between the posterior and anterior ends of the vertebral body.
  • 4. The method of claim 3, wherein said therapeutic energy is deposited in a region of the vertebral body located between 60% and 90% of the distance from the anterior wall to the posterior wall of the vertebral body.
  • 5. The method of claim 2, wherein said therapeutic energy deposited includes a region that is proximal of the BVN junction.
  • 6. The method of claim 2, wherein said therapeutic energy is deposited within a region that is at least 1 cm in diameter.
  • 7. The method of claim 2, wherein said therapeutic energy deposited comprises a steady-state heated zone having a peak temperature of between 80 degrees C. and 95 degrees C.
  • 8. The method of claim 7, wherein said steady-state heated zone heats at least 1 cc of bone to a temperature of at least 50 degrees C.
  • 9. The method of claim 2, wherein the method is performed to treat pain in a patient diagnosed with pain.
  • 10. The method of claim 1, wherein the method is performed to treat pain in a patient diagnosed with pain.
  • 11. The method of claim 1, wherein the pivotable member in the undeployed mode is entirely contained within said recess.
  • 12. The method of claim 1, wherein articulating the pivotable member from the undeployed mode to the deployed mode comprises advancing a member distally along said bore to push the free end of the of the pivotable member laterally out the recess.
  • 13. The method of claim 1, wherein the free end of the pivotable member deploys pivotably outward from the recess into the cancellous bone region.
  • 14. A method of therapeutically treating a vertebral body having an outer cortical bone region, an inner cancellous bone region, and a basivertebral nerve BVN, comprising the steps of: providing a probe configured to deploy an energy device comprising an electrode;the probe comprising a longitudinal bore extending from a proximal end of the probe toward a distal end of the probe;the probe comprising a recess in communication with said bore, said recess forming an opening at or near the distal end of the probe;the probe further comprising a pivotable member;the pivotable member having a fixed end secured to the probe at a location within the recess of the probe, and a free end configured to be extended out of the opening of the probe;wherein the pivotable member comprises an undeployed mode where the free end is not in an articulated configuration, and a deployed mode where the free end is configured to extend outward from the opening of said probe into the articulated configuration;articulating the pivotable member from the undeployed mode to the deployed mode to facilitate delivery of the energy device along a path associated with the free end of the pivotable member into the cancellous bone region of the vertebral body; andapplying a sufficiently high frequency voltage to the electrode to heat the BVN to a temperature between 80 degrees Celsius and 95 degrees Celsius and sufficient to denervate the BVN,wherein the frequency of the voltage is between 400 kHz and 600 kHz,wherein the probe comprises a sharp distal tip, andwherein the probe comprises a temperature sensor.
  • 15. The method of claim 14, wherein the electrode comprises an active electrode and wherein the probe further comprises a return electrode.
  • 16. The method of claim 14, wherein the applied high frequency voltage is configured to form a heating zone having a diameter of between 0.5 cm and 2.0 cm.
  • 17. The method of claim 14, wherein the probe has a length between 5 and 30 cm and a diameter between 0.2 mm and 10 mm.
  • 18. The method of claim 14, further comprising: piercing skin of a patient with a cannulated needle, the cannulated needle comprising a cannula and a stylet inserted within the cannula until a distal tip of the stylet extends beyond a distal opening of the cannula;advancing the cannulated needle so that the distal tip of the stylet enters within the cancellous bone region of the vertebral body;withdrawing the stylet from the cannula; andinserting at least a distal portion of the probe through a bore of the cannula and out of the distal opening of the cannula.
RELATED APPLICATIONS

This application is a divisional reissue application of U.S. patent application Ser. No. 13/541,591, filed on Jul. 3, 2012, which is an application for reissue of U.S. Pat. No. 7,749,218, which issued Jul. 6, 2010 from U.S. patent application Ser. No. 11/123,766, which is a divisional of U.S. patent application Ser. No. 10/260,879, filed Sep. 30, 2002, entitled “Method of straddling an intraosseous nerve”, now issued as U.S. Pat. No. 6,907,884, the specification of which is incorporated by reference. Notice: More than one reissue application has been filed for the reissue of U.S. Pat. No. 7,749,218. The reissue applications include the present divisional reissue application and U.S. application Ser. No. 13/541,591, filed on Jul. 3, 2012, which is a reissue application of U.S. Pat. No. 7,749,218.

US Referenced Citations (1150)
Number Name Date Kind
3565062 Kuris Feb 1971 A
3822708 Zilber Jul 1974 A
3845771 Vice Nov 1974 A
3920021 Hiltebrandt Nov 1975 A
3938502 Born Feb 1976 A
3997408 Barba et al. Dec 1976 A
4044774 Corgin et al. Aug 1977 A
4116198 Roos Sep 1978 A
4311154 Sterzer et al. Jan 1982 A
4312364 Convert et al. Jan 1982 A
4378806 Henley-Cohn Apr 1983 A
4448198 Turner May 1984 A
4449528 Auth et al. May 1984 A
4462408 Silverstein et al. Jul 1984 A
4528979 Marchenko et al. Jul 1985 A
4530360 Durate Jul 1985 A
4569351 Tang Feb 1986 A
4573448 Kambin Mar 1986 A
4586512 Do-huu May 1986 A
4601296 Yerushalmi Jul 1986 A
4612940 Kasevich et al. Sep 1986 A
4657017 Sorochenko Apr 1987 A
4662383 Sogawa et al. May 1987 A
4671293 Shalov Jun 1987 A
4676258 Inokuchi et al. Jun 1987 A
4679561 Doss Jul 1987 A
4681122 Winters et al. Jul 1987 A
4750499 Hoffer Jun 1988 A
4754757 Feucht Jul 1988 A
4757820 Itoh Jul 1988 A
4774967 Zanakis et al. Oct 1988 A
4800899 Elliott Jan 1989 A
4813429 Eshel et al. Mar 1989 A
4841977 Griffith et al. Jun 1989 A
4907589 Cosman Mar 1990 A
4924863 Sterzer May 1990 A
4936281 Stasz Jun 1990 A
4950267 Ishihara et al. Aug 1990 A
4951677 Crowley et al. Aug 1990 A
4955377 Lennox et al. Sep 1990 A
4959063 Kojima Sep 1990 A
4961435 Kitagawa et al. Oct 1990 A
4963142 Loertscher Oct 1990 A
4966144 Rochkind et al. Oct 1990 A
4967765 Turner et al. Nov 1990 A
4976711 Parins et al. Dec 1990 A
4977902 Sekino et al. Dec 1990 A
5000185 Yock Mar 1991 A
5002058 Martinelli Mar 1991 A
5002059 Crowley et al. Mar 1991 A
5007437 Sterzer Apr 1991 A
5025778 Silverstein et al. Jun 1991 A
5031618 Mullett Jul 1991 A
5061266 Hakky Oct 1991 A
5070879 Herres Dec 1991 A
RE33791 Carr Jan 1992 E
5078736 Behl Jan 1992 A
5080660 Buelna Jan 1992 A
5084043 Hertzmann et al. Jan 1992 A
5090414 Takano Feb 1992 A
5098431 Rydell Mar 1992 A
5106376 Mononen et al. Apr 1992 A
5108404 Scholten et al. Apr 1992 A
5131397 Crowley et al. Jul 1992 A
5147355 Friedman et al. Sep 1992 A
5156157 Valenta, Jr. et al. Oct 1992 A
5158536 Sekins et al. Oct 1992 A
5161533 Press et al. Nov 1992 A
5167231 Matsui Dec 1992 A
5186177 O'Donnell et al. Feb 1993 A
5190540 Lee Mar 1993 A
5190546 Jervis Mar 1993 A
5201729 Hertzmann et al. Apr 1993 A
5207672 Martinelli et al. May 1993 A
5209748 Daikuzono May 1993 A
5222953 Dowlatshahi Jun 1993 A
5226430 Spears et al. Jul 1993 A
5242439 Larsen et al. Sep 1993 A
5255679 Imran Oct 1993 A
5271408 Breyer et al. Dec 1993 A
5273026 Wilk Dec 1993 A
5281213 Milder et al. Jan 1994 A
5281215 Milder et al. Jan 1994 A
5282468 Klepinski Feb 1994 A
5292321 Lee Mar 1994 A
5295484 Marcus et al. Mar 1994 A
5300085 Yock Apr 1994 A
5304214 DeFord et al. Apr 1994 A
5305756 Entrekin et al. Apr 1994 A
5314463 Camps et al. May 1994 A
5320617 Leach Jun 1994 A
5324255 Pasafaro et al. Jun 1994 A
5325860 Seward et al. Jul 1994 A
5342292 Nita et al. Aug 1994 A
5342357 Nardella Aug 1994 A
5342409 Mullett Aug 1994 A
5344435 Turner et al. Sep 1994 A
5345940 Seward et al. Sep 1994 A
5348554 Imran et al. Sep 1994 A
5350377 Winston et al. Sep 1994 A
5351691 Brommersma Oct 1994 A
5366443 Eggers et al. Nov 1994 A
5366490 Edwards et al. Nov 1994 A
5368031 Cline et al. Nov 1994 A
5368035 Hamm et al. Nov 1994 A
5368557 Nita et al. Nov 1994 A
5368558 Nita Nov 1994 A
5370675 Edwards et al. Dec 1994 A
5370678 Edwards et al. Dec 1994 A
5372138 Crowley et al. Dec 1994 A
5374265 Sand Dec 1994 A
5383876 Nardella Jan 1995 A
5385148 Lesh et al. Jan 1995 A
5385544 Edwards et al. Jan 1995 A
5391197 Burdette et al. Feb 1995 A
5391199 Ben-Haim Feb 1995 A
5405376 Mulier et al. Apr 1995 A
5411527 Alt May 1995 A
5417719 Hull et al. May 1995 A
5419767 Eggers et al. May 1995 A
5421338 Crowley Jun 1995 A
5423811 Imran et al. Jun 1995 A
5431649 Mulier et al. Jul 1995 A
5433739 Cosman et al. Jul 1995 A
D361555 Bettin et al. Aug 1995 S
5437661 Rieser Aug 1995 A
5441499 Fritzsch Aug 1995 A
5443463 Stern Aug 1995 A
5447509 Millis et al. Sep 1995 A
5449380 Chin Sep 1995 A
5454373 Koger et al. Oct 1995 A
5458596 Lax et al. Oct 1995 A
5458597 Edwards et al. Oct 1995 A
5471988 Fujio et al. Dec 1995 A
5472441 Edwards et al. Dec 1995 A
5474530 Passafaro et al. Dec 1995 A
5484432 Sand Jan 1996 A
5486170 Winston et al. Jan 1996 A
5501703 Holsheimer et al. Mar 1996 A
5505730 Edwarrds Apr 1996 A
5514130 Baker May 1996 A
5524624 Tepper et al. Jun 1996 A
5526815 Granz et al. Jun 1996 A
5529580 Hagino et al. Jun 1996 A
5540679 Fram et al. Jul 1996 A
5540681 Strul et al. Jul 1996 A
5540684 Hassler, Jr. Jul 1996 A
5545161 Imran Aug 1996 A
5560362 Silwa, Jr. et al. Oct 1996 A
5565005 Erickson et al. Oct 1996 A
5569242 Lax et al. Oct 1996 A
5571088 Lennox et al. Nov 1996 A
5571147 Sluijter et al. Nov 1996 A
5575772 Lennox Nov 1996 A
5575788 Baker et al. Nov 1996 A
5588432 Crowley Dec 1996 A
5596988 Markle et al. Jan 1997 A
5601526 Chapelon et al. Feb 1997 A
5606974 Castellano et al. Mar 1997 A
5609151 Mulier et al. Mar 1997 A
5620479 Diederich Apr 1997 A
5628317 Starkebaum et al. May 1997 A
5630426 Shmulewitz et al. May 1997 A
5630837 Crowley May 1997 A
5643319 Green et al. Jul 1997 A
5643330 Holshiemer et al. Jul 1997 A
5647361 Damadian Jul 1997 A
5647871 Levine et al. Jul 1997 A
5658278 Imran et al. Aug 1997 A
5672173 Gough et al. Sep 1997 A
5681282 Eggers et al. Oct 1997 A
5683366 Eggers et al. Nov 1997 A
5685839 Baker et al. Nov 1997 A
5687729 Schaetzle Nov 1997 A
5688267 Panescu Nov 1997 A
5693052 Weaver Dec 1997 A
5697281 Eggers et al. Dec 1997 A
5697536 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5697909 Eggers et al. Dec 1997 A
5697927 Imran et al. Dec 1997 A
5700262 Acosta et al. Dec 1997 A
5718231 Chen et al. Feb 1998 A
5720286 Chapelon et al. Feb 1998 A
5720287 Chapelon et al. Feb 1998 A
5722403 McGee et al. Mar 1998 A
5725494 Brisken Mar 1998 A
5728062 Brisken Mar 1998 A
5730706 Garnies Mar 1998 A
5733315 Burdette et al. Mar 1998 A
5735280 Sherman et al. Apr 1998 A
5735811 Brisken Apr 1998 A
5735846 Fleischman et al. Apr 1998 A
5735847 Gough et al. Apr 1998 A
5738680 Mueller et al. Apr 1998 A
5741249 Moss et al. Apr 1998 A
5743904 Edwards Apr 1998 A
5746737 Saadat May 1998 A
5752969 Cunci et al. May 1998 A
5755663 Johnson et al. May 1998 A
5762066 Law et al. Jun 1998 A
5762616 Talish Jun 1998 A
5766153 Eggers et al. Jun 1998 A
5766231 Erickson et al. Jun 1998 A
5776092 Farin et al. Jul 1998 A
5785705 Baker Jul 1998 A
5800378 Edwards et al. Sep 1998 A
5800429 Edwards Sep 1998 A
5800432 Swanson Sep 1998 A
5807237 Tindel Sep 1998 A
5807391 Wijkamp Sep 1998 A
5807392 Eggers Sep 1998 A
5807395 Mulier et al. Sep 1998 A
5810764 Eggers et al. Sep 1998 A
5817021 Reichenberger Oct 1998 A
5824021 Rise Oct 1998 A
5840031 Crowley Nov 1998 A
5843019 Eggers et al. Dec 1998 A
5843021 Edwards et al. Dec 1998 A
5844092 Presta et al. Dec 1998 A
5846218 Brisken et al. Dec 1998 A
5849011 Jones et al. Dec 1998 A
5855576 LeVeen et al. Jan 1999 A
5860951 Eggers et al. Jan 1999 A
5865788 Edwards et al. Feb 1999 A
5865801 Houser Feb 1999 A
5868740 LeVeen et al. Feb 1999 A
5871469 Eggers et al. Feb 1999 A
5871470 McWha Feb 1999 A
5871481 Kannenberg et al. Feb 1999 A
5873855 Eggers et al. Feb 1999 A
5873877 McGaffigan et al. Feb 1999 A
5876398 Mulier et al. Mar 1999 A
5888198 Eggers et al. Mar 1999 A
5891095 Eggers et al. Apr 1999 A
5895370 Edwards et al. Apr 1999 A
5902272 Eggers et al. May 1999 A
5902308 Murphy May 1999 A
5904681 West, Jr. May 1999 A
5906613 Mulier et al. May 1999 A
5916213 Haissaguerre et al. Jun 1999 A
5916214 Cosio Jun 1999 A
5919188 Shearon et al. Jul 1999 A
5931805 Brisken Aug 1999 A
5935123 Edwards et al. Aug 1999 A
5938582 Ciamacco et al. Aug 1999 A
5941722 Chen Aug 1999 A
5941876 Nardella et al. Aug 1999 A
5944715 Goble et al. Aug 1999 A
5948007 Starkebaum et al. Sep 1999 A
5948008 Daikuzono Sep 1999 A
5954716 Sharkey et al. Sep 1999 A
5964727 Edwards et al. Oct 1999 A
5967988 Briscoe et al. Oct 1999 A
5976105 Marcove et al. Nov 1999 A
5983141 Sluijter et al. Nov 1999 A
5997497 Nita et al. Dec 1999 A
6001095 de la Rama et al. Dec 1999 A
6007533 Casscells et al. Dec 1999 A
6007570 Sharkey et al. Dec 1999 A
6012457 Lesh Jan 2000 A
6014588 Fitz Jan 2000 A
6016452 Kasevich Jan 2000 A
6016809 Mulier et al. Jan 2000 A
6017356 Frederick et al. Jan 2000 A
6019776 Preissman et al. Feb 2000 A
6022334 Edwards et al. Feb 2000 A
6024733 Eggers et al. Feb 2000 A
6024740 Lesh et al. Feb 2000 A
6030374 McDaniel Feb 2000 A
6030402 Thompson et al. Feb 2000 A
6032673 Langberg et al. Mar 2000 A
6032674 Eggers et al. Mar 2000 A
6033411 Preissman et al. Mar 2000 A
6035238 Ingle et al. Mar 2000 A
6038480 Hrdlicka et al. Mar 2000 A
6045532 Eggers et al. Apr 2000 A
6046187 Berde et al. Apr 2000 A
6047214 Mueller et al. Apr 2000 A
6050995 Durgin Apr 2000 A
6053172 Hovda et al. Apr 2000 A
6053909 Shadduck Apr 2000 A
6063078 Wittkampf May 2000 A
6063079 Hovda et al. May 2000 A
6066134 Eggers et al. May 2000 A
6066139 Ryan et al. May 2000 A
6068642 Johnson et al. May 2000 A
6071279 Whayne et al. Jun 2000 A
6073051 Sharkey et al. Jun 2000 A
6074352 Hynynen et al. Jun 2000 A
6086585 Hovda et al. Jul 2000 A
6090105 Zepeda et al. Jul 2000 A
6095149 Sharkey et al. Aug 2000 A
6099499 Ciamacco Aug 2000 A
6099514 Sharkey et al. Aug 2000 A
6102046 Weinstein et al. Aug 2000 A
6104957 Alo et al. Aug 2000 A
6105581 Eggers et al. Aug 2000 A
6106454 Berg et al. Aug 2000 A
6109268 Thapliyal et al. Aug 2000 A
6112122 Schwardt et al. Aug 2000 A
6113597 Eggers et al. Sep 2000 A
6117101 Diederich et al. Sep 2000 A
6117109 Eggers et al. Sep 2000 A
6117128 Gregory Sep 2000 A
6120467 Schallhorn Sep 2000 A
6120502 Michelson Sep 2000 A
6122549 Sharkey et al. Sep 2000 A
6126682 Ashley et al. Oct 2000 A
6137209 Dahlberg et al. Oct 2000 A
6139545 Utley et al. Oct 2000 A
6142992 Cheng et al. Nov 2000 A
6143019 Motamedi et al. Nov 2000 A
6146380 Racz et al. Nov 2000 A
6149620 Baker et al. Nov 2000 A
6159194 Eggers et al. Dec 2000 A
6159208 Hovda et al. Dec 2000 A
6161048 Sluijter et al. Dec 2000 A
6164283 Lesh Dec 2000 A
6165172 Farley et al. Dec 2000 A
6168593 Sharkey et al. Jan 2001 B1
6169924 Meloy et al. Jan 2001 B1
6171239 Humphrey Jan 2001 B1
6176857 Ashley Jan 2001 B1
6179824 Eggers et al. Jan 2001 B1
6179836 Eggers et al. Jan 2001 B1
6179858 Squire et al. Jan 2001 B1
6183469 Thapliyal et al. Feb 2001 B1
6190381 Olsen et al. Feb 2001 B1
6190383 Schmaltz et al. Feb 2001 B1
6193715 Wrublewski et al. Feb 2001 B1
6203542 Ellsberry et al. Mar 2001 B1
6206842 Tu et al. Mar 2001 B1
6210393 Brisken Apr 2001 B1
6210402 Olsen et al. Apr 2001 B1
6210415 Bester Apr 2001 B1
6216704 Ingle et al. Apr 2001 B1
6221038 Brisken Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6228046 Brisken May 2001 B1
6228078 Eggers et al. May 2001 B1
6228082 Baker et al. May 2001 B1
6231516 Keilman et al. May 2001 B1
6231528 Kaufman et al. May 2001 B1
6231571 Ellman et al. May 2001 B1
6231615 Preissman May 2001 B1
6233488 Hess May 2001 B1
6235020 Cheng et al. May 2001 B1
6235024 Tu May 2001 B1
6238391 Olsen et al. May 2001 B1
6238393 Mulier et al. May 2001 B1
6241665 Negus et al. Jun 2001 B1
6241725 Cosman Jun 2001 B1
6245064 Lesh Jun 2001 B1
6246912 Sluijter et al. Jun 2001 B1
6248345 Goldenheim et al. Jun 2001 B1
6254553 Lidgren et al. Jul 2001 B1
6254599 Lesh et al. Jul 2001 B1
6254600 Willink et al. Jul 2001 B1
6258086 Ashley et al. Jul 2001 B1
6259952 Sluijter Jul 2001 B1
6261311 Sharkey et al. Jul 2001 B1
6264650 Hovda et al. Jul 2001 B1
6264651 Underwood et al. Jul 2001 B1
6264652 Eggers et al. Jul 2001 B1
6264659 Ross et al. Jul 2001 B1
6267770 Truwit Jul 2001 B1
6270498 Michelson Aug 2001 B1
6277112 Underwood et al. Aug 2001 B1
6277122 McGahan et al. Aug 2001 B1
6280441 Ryan Aug 2001 B1
6283961 Underwood et al. Sep 2001 B1
6287114 Meller et al. Sep 2001 B1
6287272 Brisken et al. Sep 2001 B1
6287304 Eggers et al. Sep 2001 B1
6290715 Sharkey et al. Sep 2001 B1
6292699 Simon et al. Sep 2001 B1
6296619 Brisken et al. Oct 2001 B1
6296636 Cheng et al. Oct 2001 B1
6296638 Davison et al. Oct 2001 B1
6305378 Lesh et al. Oct 2001 B1
6309387 Eggers et al. Oct 2001 B1
6309420 Preissman Oct 2001 B1
6312408 Eggers et al. Nov 2001 B1
6312426 Goldberg et al. Nov 2001 B1
6319241 King et al. Nov 2001 B1
6322549 Eggers et al. Nov 2001 B1
6348055 Preissman Feb 2002 B1
6355032 Hovda et al. Mar 2002 B1
6356790 Maguire et al. Mar 2002 B1
6361531 Hissong Mar 2002 B1
6363937 Hovda et al. Apr 2002 B1
6368292 Ogden et al. Apr 2002 B1
6379351 Thapliyal et al. Apr 2002 B1
6383190 Preissman May 2002 B1
6391025 Weinstein et al. May 2002 B1
6416507 Eggers et al. Jul 2002 B1
6416508 Eggers et al. Jul 2002 B1
6423059 Hanson et al. Jul 2002 B1
6426339 Berde et al. Jul 2002 B1
6428491 Weiss Aug 2002 B1
6432103 Ellsberry et al. Aug 2002 B1
6436060 Talish Aug 2002 B1
6436098 Michelson Aug 2002 B1
6447448 Ishikawa et al. Sep 2002 B1
6451013 Bays et al. Sep 2002 B1
6454727 Bubank et al. Sep 2002 B1
6461350 Underwood et al. Oct 2002 B1
6461354 Olsen et al. Oct 2002 B1
6464695 Hovda et al. Oct 2002 B2
6468270 Hovda et al. Oct 2002 B1
6468274 Alleyne et al. Oct 2002 B1
6470220 Kraus et al. Oct 2002 B1
6478793 Cosman et al. Nov 2002 B1
6482201 Olsen et al. Nov 2002 B1
6485271 Tack Nov 2002 B1
6487446 Hill et al. Nov 2002 B1
6491893 Babich Dec 2002 B1
6493592 Leonard et al. Dec 2002 B1
6494902 Hoey et al. Dec 2002 B2
6500173 Underwood et al. Dec 2002 B2
6505075 Weiner Jan 2003 B1
6508839 Lambrecht et al. Jan 2003 B1
6524261 Talish et al. Feb 2003 B2
6537306 Burdette et al. Feb 2003 B1
6527759 Tachibana et al. Mar 2003 B1
6540741 Underwood et al. Apr 2003 B1
6544261 Ellsberry et al. Apr 2003 B2
6557559 Eggers et al. May 2003 B1
6558385 McClurken et al. May 2003 B1
6558390 Cragg May 2003 B2
6560486 Osorio et al. May 2003 B1
6562033 Shah et al. May 2003 B2
6575968 Eggers et al. Jun 2003 B1
6575969 Rittman, III et al. Jun 2003 B1
6575979 Cragg Jun 2003 B1
6578579 Burnside et al. Jun 2003 B2
6582423 Thapliyal et al. Jun 2003 B1
6585656 Masters Jul 2003 B2
6589237 Woloszko et al. Jul 2003 B2
6592559 Pakter et al. Jul 2003 B1
6595990 Weinstein et al. Jul 2003 B1
6599288 Maguire et al. Jul 2003 B2
6602248 Sharps et al. Aug 2003 B1
6604003 Fredricks et al. Aug 2003 B2
6607502 Maguire et al. Aug 2003 B1
6607529 Jones et al. Aug 2003 B1
6608502 Aoki et al. Aug 2003 B2
6622731 Daniel et al. Sep 2003 B2
6632193 Davison et al. Oct 2003 B1
6632220 Eggers et al. Oct 2003 B1
6645202 Pless et al. Nov 2003 B1
6648883 Francischelli et al. Nov 2003 B2
6659106 Hovda et al. Dec 2003 B1
6663627 Francischelli et al. Dec 2003 B2
6673063 Brett Jan 2004 B2
6689086 Nita et al. Feb 2004 B1
6689125 Keith et al. Feb 2004 B1
6692450 Coleman Feb 2004 B1
6699240 Francischelli Mar 2004 B2
6699242 Heggeness Mar 2004 B2
6709432 Ferek-Patric Mar 2004 B2
6718208 Hill et al. Apr 2004 B2
6723087 O'Neill et al. Apr 2004 B2
6726684 Woloszko et al. Apr 2004 B1
6736810 Hoey et al. May 2004 B2
6736835 Pellegrino et al. May 2004 B2
6745079 King Jun 2004 B2
6746447 Davison et al. Jun 2004 B2
6749604 Eggers et al. Jun 2004 B1
6758846 Goble et al. Jul 2004 B2
6770071 Woloszko et al. Aug 2004 B2
6772012 Ricart et al. Aug 2004 B2
6773431 Eggers et al. Aug 2004 B2
6795737 Gielen et al. Sep 2004 B2
6827715 Francischelli et al. Dec 2004 B2
6827716 Ryan et al. Dec 2004 B2
6832996 Woloszko et al. Dec 2004 B2
6837887 Woloszko et al. Jan 2005 B2
6837888 Ciarrocca et al. Jan 2005 B2
6852091 Edwards et al. Feb 2005 B2
6863672 Reiley et al. Mar 2005 B2
6875219 Arramon et al. Apr 2005 B2
6881214 Cosman et al. Apr 2005 B2
6896674 Woloszko et al. May 2005 B1
6896675 Leung et al. May 2005 B2
6907884 Pellegrino et al. Jun 2005 B2
6915806 Pacek et al. Jul 2005 B2
6922579 Taimisto et al. Jul 2005 B2
6923813 Phillips et al. Aug 2005 B2
6936046 Hissong et al. Aug 2005 B2
6955674 Eick et al. Oct 2005 B2
6960204 Eggers et al. Nov 2005 B2
6962589 Mulier et al. Nov 2005 B2
6974453 Woloszko et al. Dec 2005 B2
6980849 Sasso Dec 2005 B2
6989010 Francischelli et al. Jan 2006 B2
6997941 Sharkey et al. Feb 2006 B2
7048743 Miller et al. May 2006 B2
7065408 Herman et al. Jun 2006 B2
7081122 Reiley et al. Jul 2006 B1
7090672 Underwood et al. Aug 2006 B2
7104989 Skarda Sep 2006 B2
7131969 Hovda et al. Nov 2006 B1
7177678 Osorio et al. Feb 2007 B1
7179255 Lettice et al. Feb 2007 B2
7186234 Dahla et al. Mar 2007 B2
7192428 Eggers et al. Mar 2007 B2
7201731 Lundquist et al. Apr 2007 B1
7201750 Eggers et al. Apr 2007 B1
7211055 Diederich et al. May 2007 B2
7217268 Eggers et al. May 2007 B2
7250048 Francischelli et al. Jul 2007 B2
7258690 Sutton et al. Aug 2007 B2
7270659 Ricart et al. Sep 2007 B2
7270661 Dahla et al. Sep 2007 B2
7276063 Davison et al. Oct 2007 B2
7294127 Leung et al. Nov 2007 B2
7305264 Larson et al. Dec 2007 B2
7306596 Hillier et al. Dec 2007 B2
7318823 Sharps et al. Jan 2008 B2
7326203 Papineau et al. Feb 2008 B2
7331956 Hovda et al. Feb 2008 B2
7331957 Woloszko et al. Feb 2008 B2
RE40156 Sharps et al. Mar 2008 E
7346391 Osorio et al. Mar 2008 B1
7386350 Vilims Jun 2008 B2
7387625 Hovda et al. Jun 2008 B2
7393351 Woloszko et al. Jul 2008 B2
7422585 Eggers et al. Sep 2008 B1
7429262 Woloszko et al. Sep 2008 B2
7435247 Woloszko et al. Oct 2008 B2
7435250 Francischelli et al. Oct 2008 B2
7442191 Hovda et al. Oct 2008 B2
7468059 Eggers et al. Dec 2008 B2
7480533 Cosman et al. Jan 2009 B2
7502652 Gaunt et al. Mar 2009 B2
7503921 Siegel Mar 2009 B2
7507236 Eggers et al. Mar 2009 B2
7546164 King Jun 2009 B2
7553307 Bleich et al. Jun 2009 B2
7553309 Buysse et al. Jun 2009 B2
7555343 Bleich Jun 2009 B2
7593778 Chandran et al. Sep 2009 B2
7645277 McClurken et al. Jan 2010 B2
7678111 Mulier et al. Mar 2010 B2
7708733 Sanders et al. May 2010 B2
7738968 Bleich Jun 2010 B2
7740631 Bleich et al. Jun 2010 B2
7749218 Pellegrino et al. Jul 2010 B2
7749220 Schmaltz et al. Jul 2010 B2
7819826 Diederich et al. Oct 2010 B2
7819869 Godara et al. Oct 2010 B2
7824398 Woloszko et al. Nov 2010 B2
7824404 Godara et al. Nov 2010 B2
7846156 Malis et al. Dec 2010 B2
7850685 Kunis et al. Dec 2010 B2
7857813 Schmitz et al. Dec 2010 B2
7896870 Arless et al. Mar 2011 B2
7901403 Woloszko et al. Mar 2011 B2
7909827 Reiley et al. Mar 2011 B2
7914526 Lehmann et al. Mar 2011 B2
7917222 Osorio et al. Mar 2011 B1
7918849 Bleich et al. Apr 2011 B2
7918874 Siegal Apr 2011 B2
7945331 Vilims May 2011 B2
7951140 Arless et al. May 2011 B2
7963915 Bleich Jun 2011 B2
7969634 Sennett Jun 2011 B2
8021401 Carl et al. Sep 2011 B2
8025688 Diederich et al. Sep 2011 B2
8034052 Podhajsky Oct 2011 B2
8062290 Buysse et al. Nov 2011 B2
8066702 Rittman, III et al. Nov 2011 B2
8083736 McClurken et al. Dec 2011 B2
8100896 Podhajsky Jan 2012 B2
8128633 Linderman et al. Mar 2012 B2
8162933 Francischelli et al. Apr 2012 B2
8172846 Brunnett et al. May 2012 B2
8182477 Orszulak et al. May 2012 B2
8192424 Woloszko et al. Jun 2012 B2
8192435 Bleich et al. Jun 2012 B2
8265747 Rittman, III et al. Sep 2012 B2
8282628 Paul et al. Oct 2012 B2
8292887 Woloszko et al. Oct 2012 B2
8323279 Dahla et al. Dec 2012 B2
8348946 McClurken et al. Jan 2013 B2
8355799 Marion et al. Jan 2013 B2
8361067 Pellegrino et al. Jan 2013 B2
8414509 Diederich et al. Apr 2013 B2
8414571 Pellegrino et al. Apr 2013 B2
8419730 Pellegrino et al. Apr 2013 B2
8419731 Pellegrino et al. Apr 2013 B2
8425507 Pellegrino et al. Apr 2013 B2
8444640 Demarais et al. May 2013 B2
8454594 Demarais et al. Jun 2013 B2
8475449 Werneth et al. Jul 2013 B2
8486063 Werneth et al. Jul 2013 B2
8504147 Deem et al. Aug 2013 B2
8535309 Pellegrino et al. Sep 2013 B2
8579903 Carl Nov 2013 B2
8597301 Mitchell Dec 2013 B2
8613744 Pellegrino et al. Dec 2013 B2
8617156 Werneth et al. Dec 2013 B2
8623014 Pellegrino et al. Jan 2014 B2
8628528 Pellegrino et al. Jan 2014 B2
8644941 Rooney et al. Feb 2014 B2
8657814 Werneth et al. Feb 2014 B2
8676309 Deem et al. Mar 2014 B2
8690884 Linderman et al. Apr 2014 B2
8747359 Pakter et al. Jun 2014 B2
8747398 Behnke Jun 2014 B2
8758349 Germain et al. Jun 2014 B2
8771276 Linderman Jul 2014 B2
8774913 Demarais et al. Jul 2014 B2
8774924 Weiner Jul 2014 B2
8795270 Drake Aug 2014 B2
8808161 Gregg et al. Aug 2014 B2
8808284 Pellegrino et al. Aug 2014 B2
8821488 Stewart et al. Sep 2014 B2
8845631 Werneth et al. Sep 2014 B2
8864760 Kramer et al. Oct 2014 B2
8882755 Leung et al. Nov 2014 B2
8882759 Manley et al. Nov 2014 B2
8882764 Pellegrino et al. Nov 2014 B2
8894658 Linderman et al. Nov 2014 B2
8915949 Diederich et al. Dec 2014 B2
8926620 Chasmawala et al. Jan 2015 B2
8968288 Brannan Mar 2015 B2
8989859 Deem et al. Mar 2015 B2
8992522 Pellegrino et al. Mar 2015 B2
8992523 Pellegrino et al. Mar 2015 B2
9017325 Pellegrino et al. Apr 2015 B2
9023038 Pellegrino et al. May 2015 B2
9028488 Goshayeshgar May 2015 B2
9028538 Paul et al. May 2015 B2
9039701 Pellegrino et al. May 2015 B2
9044245 Condie et al. Jun 2015 B2
9044254 Ladtkow et al. Jun 2015 B2
9044575 Beasley et al. Jun 2015 B2
9095359 Robert et al. Aug 2015 B2
9113896 Mulier et al. Aug 2015 B2
9113911 Sherman Aug 2015 B2
9113925 Smith et al. Aug 2015 B2
9119647 Brannan Sep 2015 B2
9119650 Brannan et al. Sep 2015 B2
9125671 Germain et al. Sep 2015 B2
9131597 Taft et al. Sep 2015 B2
9151680 Brannan Oct 2015 B2
9155895 Wacnik et al. Oct 2015 B2
9161735 Bradford et al. Oct 2015 B2
9161805 Isenberg Oct 2015 B2
9161814 Brannan et al. Oct 2015 B2
9168078 Linderman et al. Oct 2015 B2
9168085 Juzkiw Oct 2015 B2
9173676 Pellegrino et al. Nov 2015 B2
9173700 Godara et al. Nov 2015 B2
9179970 Utley et al. Nov 2015 B2
9186197 McKay Nov 2015 B2
9192308 Brannan et al. Nov 2015 B2
9198684 Arthur et al. Dec 2015 B2
9226756 Teisen et al. Jan 2016 B2
9237916 Crainich et al. Jan 2016 B2
9238139 Degiorgio et al. Jan 2016 B2
9241729 Juntz et al. Jan 2016 B2
9241760 Godara et al. Jan 2016 B2
9247992 Ladtkow et al. Feb 2016 B2
9247993 Ladtkow et al. Feb 2016 B2
9248278 Crosby et al. Feb 2016 B2
9248289 Bennett et al. Feb 2016 B2
9254168 Palanker Feb 2016 B2
9254386 Lee et al. Feb 2016 B2
9259241 Pellegrino et al. Feb 2016 B2
9259248 Leuthardt et al. Feb 2016 B2
9259269 Ladtkow et al. Feb 2016 B2
9259569 Brounstein et al. Feb 2016 B2
9259577 Kaula et al. Feb 2016 B2
9265522 Pellegrino et al. Feb 2016 B2
9265557 Sherman et al. Feb 2016 B2
9277969 Brannan et al. Mar 2016 B2
9282988 Goshayeshgar Mar 2016 B2
9289607 Su et al. Mar 2016 B2
9295517 Peyman et al. Mar 2016 B2
9295841 Fang et al. Mar 2016 B2
9301723 Brannan et al. Apr 2016 B2
9301804 Bonn Apr 2016 B2
9302117 De Vincentiis Apr 2016 B2
9308036 Robinson Apr 2016 B2
9308045 Kim et al. Apr 2016 B2
9314252 Schaller et al. Apr 2016 B2
9314613 Mashiach Apr 2016 B2
9314618 Imran et al. Apr 2016 B2
9333144 Baxter et al. May 2016 B2
9333339 Weiner May 2016 B2
9333361 Li et al. May 2016 B2
9333373 Imran May 2016 B2
9339655 Carbunaru May 2016 B2
9345530 Ballakur et al. May 2016 B2
9345537 Harrison et al. May 2016 B2
9345538 Deem et al. May 2016 B2
9351739 Mahoney et al. May 2016 B2
9358067 Lee et al. Jun 2016 B2
9358396 Holley Jun 2016 B2
9364286 Werneth et al. Jun 2016 B2
9370348 Tally et al. Jun 2016 B2
9370392 Sharonov Jun 2016 B2
9370398 Ladtkow et al. Jun 2016 B2
9375274 Reid Jun 2016 B2
9375275 Lee et al. Jun 2016 B2
9375278 Robert et al. Jun 2016 B2
9375279 Brannan Jun 2016 B2
9375283 Arts et al. Jun 2016 B2
9381024 Globerman et al. Jul 2016 B2
9381045 Donner et al. Jul 2016 B2
9381050 Lee et al. Jul 2016 B2
9381359 Parramon et al. Jul 2016 B2
9387094 Manrique et al. Jul 2016 B2
9393416 Rooney et al. Jul 2016 B2
9398931 Wittenberger et al. Jul 2016 B2
9399144 Howard Jul 2016 B2
9403038 Tyler Aug 2016 B2
9409023 Burdick et al. Aug 2016 B2
9414884 Faehndrich et al. Aug 2016 B2
9421064 Pellegrino et al. Aug 2016 B2
9421123 Lee et al. Aug 2016 B2
9421371 Pless et al. Aug 2016 B2
9421378 Lian et al. Aug 2016 B2
9439693 Childs et al. Sep 2016 B2
9439721 Werneth et al. Sep 2016 B2
9445859 Childs et al. Sep 2016 B2
9446229 Omar-Pasha Sep 2016 B2
9446235 Su et al. Sep 2016 B2
9452286 Cowan et al. Sep 2016 B2
9456836 Boling et al. Oct 2016 B2
9457182 Koop Oct 2016 B2
9468485 Wittenberger et al. Oct 2016 B2
9468495 Kunis et al. Oct 2016 B2
9474906 Sachs et al. Oct 2016 B2
9486279 Pellegrino et al. Nov 2016 B2
9486447 Peterson et al. Nov 2016 B2
9486621 Howard et al. Nov 2016 B2
9492657 Gerber Nov 2016 B2
9492664 Peterson Nov 2016 B2
9504372 Kim Nov 2016 B2
9504518 Condie et al. Nov 2016 B2
9504530 Hartmann et al. Nov 2016 B2
9504818 Moffitt et al. Nov 2016 B2
9511229 Bradley Dec 2016 B2
9511231 Kent et al. Dec 2016 B1
9517200 Bleier Dec 2016 B2
9526507 Germain Dec 2016 B2
9526551 Linderman Dec 2016 B2
9532828 Condie et al. Jan 2017 B2
9549772 Carl Jan 2017 B2
9550041 Bedell Jan 2017 B2
9555037 Podhajsky Jan 2017 B2
9566449 Perryman et al. Feb 2017 B2
9572976 Howard et al. Feb 2017 B2
9572986 Moffitt Feb 2017 B2
9579518 Gertner Feb 2017 B2
9597148 Olson Mar 2017 B2
RE46356 Pellegrino Apr 2017 E
9610117 Germain Apr 2017 B2
9649116 Germain May 2017 B2
9687255 Sennett et al. Jun 2017 B2
9724107 Pellegrino et al. Aug 2017 B2
9724151 Edidin Aug 2017 B2
9730707 Sasaki et al. Aug 2017 B2
9770280 Diederich et al. Sep 2017 B2
9775627 Patel et al. Oct 2017 B2
9782221 Srinivasan Oct 2017 B2
9795802 Mohamed et al. Oct 2017 B2
9848944 Sutton et al. Dec 2017 B2
10028753 Pellegrino et al. Jul 2018 B2
10111704 Pellegrino et al. Oct 2018 B2
10265099 Pellegrino et al. Apr 2019 B2
10272271 Diederich et al. Apr 2019 B2
10357258 Patel et al. Jul 2019 B2
10390877 Heggeness et al. Aug 2019 B2
10456187 Edidin Oct 2019 B2
10463380 Purdy et al. Nov 2019 B2
10463423 Sutton et al. Nov 2019 B2
10470781 Purdy et al. Nov 2019 B2
10478246 Pellegrino et al. Nov 2019 B2
10517611 Patel et al. Dec 2019 B2
10588691 Pellegrino et al. Mar 2020 B2
10589131 Diederich et al. Mar 2020 B2
10603522 Diederich et al. Mar 2020 B2
20010001314 Davison et al. May 2001 A1
20010001811 Burney et al. May 2001 A1
20010020167 Woloszko et al. Sep 2001 A1
20010023348 Ashley et al. Sep 2001 A1
20010025176 Ellsberry et al. Sep 2001 A1
20010025177 Woloszko et al. Sep 2001 A1
20010027295 Dulak et al. Oct 2001 A1
20010029370 Hodva et al. Oct 2001 A1
20010029373 Baker et al. Oct 2001 A1
20010029393 Tierney et al. Oct 2001 A1
20010032001 Ricart et al. Oct 2001 A1
20010047167 Heggeness Nov 2001 A1
20010049522 Eggers et al. Dec 2001 A1
20010049527 Cragg Dec 2001 A1
20010051802 Woloszko et al. Dec 2001 A1
20010053885 Gielen et al. Dec 2001 A1
20010056280 Underwood et al. Dec 2001 A1
20020016600 Cosman Feb 2002 A1
20020019626 Sharkey et al. Feb 2002 A1
20020026186 Woloszko et al. Feb 2002 A1
20020049438 Sharkey et al. Apr 2002 A1
20020095144 Carl Apr 2002 A1
20020052600 Davison et al. May 2002 A1
20020068930 Tasto et al. Jun 2002 A1
20020095151 Dahla et al. Jul 2002 A1
20020095152 Ciarrocca et al. Jul 2002 A1
20020099366 Dahla et al. Jul 2002 A1
20020111661 Cross et al. Aug 2002 A1
20020115945 D'Luzansky et al. Aug 2002 A1
20020120259 Lettice Aug 2002 A1
20020147444 Shah et al. Oct 2002 A1
20020151885 Underwood et al. Oct 2002 A1
20020188284 To et al. Dec 2002 A1
20020188290 Sharkey et al. Dec 2002 A1
20020193708 Thompson et al. Dec 2002 A1
20020193789 Underwood et al. Dec 2002 A1
20030009164 Woloszko et al. Jan 2003 A1
20030014047 Woloszko et al. Jan 2003 A1
20030014088 Fang et al. Jan 2003 A1
20030028147 Aves et al. Feb 2003 A1
20030028189 Woloszko et al. Feb 2003 A1
20030040742 Underwood et al. Feb 2003 A1
20030055418 Tasto et al. Mar 2003 A1
20030069569 Burdette et al. Apr 2003 A1
20030083592 Faciszewski May 2003 A1
20030084907 Pacek et al. May 2003 A1
20030097126 Woloszko et al. May 2003 A1
20030097129 Davison et al. May 2003 A1
20030130655 Woloszko et al. Jul 2003 A1
20030139652 Kang et al. Jul 2003 A1
20030158545 Hovda et al. Aug 2003 A1
20030181963 Pellegrino et al. Sep 2003 A1
20030208194 Hovda et al. Nov 2003 A1
20030216725 Woloszko et al. Nov 2003 A1
20030216726 Eggers et al. Nov 2003 A1
20030225364 Kraft Dec 2003 A1
20040006339 Underwood et al. Jan 2004 A1
20040024399 Sharps et al. Feb 2004 A1
20040054366 Davison et al. Mar 2004 A1
20040064023 Thomas et al. Apr 2004 A1
20040064136 Crombie et al. Apr 2004 A1
20040064137 Pellegrino et al. Apr 2004 A1
20040068242 McGuckin, Jr. Apr 2004 A1
20040082942 Katzman Apr 2004 A1
20040087937 Eggers et al. May 2004 A1
20040116922 Hovda et al. Jun 2004 A1
20040120891 Hill et al. Jun 2004 A1
20040133124 Bates et al. Jul 2004 A1
20040162559 Arramon Aug 2004 A1
20040186544 King Sep 2004 A1
20040193151 To et al. Sep 2004 A1
20040220577 Cragg et al. Nov 2004 A1
20040225228 Ferree Nov 2004 A1
20040230190 Dahla et al. Nov 2004 A1
20050004634 Ricart et al. Jan 2005 A1
20050010095 Stewart et al. Jan 2005 A1
20050010203 Edwards et al. Jan 2005 A1
20050010205 Hovda et al. Jan 2005 A1
20050055096 Serhan et al. Mar 2005 A1
20050177210 Leung et al. Aug 2005 A1
20050177211 Leung et al. Aug 2005 A1
20050182417 Pagano Aug 2005 A1
20050192564 Cosman et al. Sep 2005 A1
20050209659 Pellegrino et al. Sep 2005 A1
20050234445 Conquergood et al. Oct 2005 A1
20050261754 Woloszko Nov 2005 A1
20050267552 Conquergood et al. Dec 2005 A1
20050278007 Godara Dec 2005 A1
20050283148 Janssen et al. Dec 2005 A1
20060004369 Patel et al. Jan 2006 A1
20060052743 Reynolds Mar 2006 A1
20060064101 Arramon Mar 2006 A1
20060095026 Ricart et al. May 2006 A1
20060095028 Bleich May 2006 A1
20060106375 Werneth et al. May 2006 A1
20060106376 Godara et al. May 2006 A1
20060122458 Bleich Jun 2006 A1
20060129101 McGuckin Jun 2006 A1
20060178670 Woloszko et al. Aug 2006 A1
20060206128 Conquergood et al. Sep 2006 A1
20060206129 Conquergood et al. Sep 2006 A1
20060206130 Conquergood et al. Sep 2006 A1
20060206132 Conquergood et al. Sep 2006 A1
20060206133 Conquergood et al. Sep 2006 A1
20060206134 Conquergood et al. Sep 2006 A1
20060206166 Weiner Sep 2006 A1
20060229625 Truckai et al. Oct 2006 A1
20060253117 Hovda et al. Nov 2006 A1
20060259026 Godara et al. Nov 2006 A1
20060264957 Cragg et al. Nov 2006 A1
20060264965 Shadduck et al. Nov 2006 A1
20060265014 Demarais et al. Nov 2006 A1
20060276749 Selmon et al. Dec 2006 A1
20070027449 Godara et al. Feb 2007 A1
20070055316 Godara et al. Mar 2007 A1
20070118142 Krueger et al. May 2007 A1
20070129715 Eggers et al. Jun 2007 A1
20070142791 Yeung et al. Jun 2007 A1
20070142842 Kreuger et al. Jun 2007 A1
20070149966 Dahla et al. Jun 2007 A1
20070179497 Eggers et al. Aug 2007 A1
20070213584 Kim et al. Sep 2007 A1
20070213735 Saadat et al. Sep 2007 A1
20070260237 Sutton et al. Nov 2007 A1
20080004621 Dahla et al. Jan 2008 A1
20080004675 King et al. Jan 2008 A1
20080009847 Ricart et al. Jan 2008 A1
20080021447 Davison et al. Jan 2008 A1
20080021463 Georgy Jan 2008 A1
20080058707 Ashley et al. Mar 2008 A1
20080065062 Leung et al. Mar 2008 A1
20080091207 Truckai et al. Apr 2008 A1
20080114364 Goldin et al. May 2008 A1
20080119844 Woloszko et al. May 2008 A1
20080119846 Rioux May 2008 A1
20080132890 Woloszko et al. Jun 2008 A1
20080161804 Rioux et al. Jul 2008 A1
20080275458 Bleich et al. Nov 2008 A1
20080281322 Sherman et al. Nov 2008 A1
20080294166 Goldin et al. Nov 2008 A1
20090030308 Bradford et al. Jan 2009 A1
20090054951 Lauthardt et al. Feb 2009 A1
20090069807 Eggers et al. Mar 2009 A1
20090105775 Mitchell et al. Apr 2009 A1
20090112278 Wingeier et al. Apr 2009 A1
20090118731 Young et al. May 2009 A1
20090131867 Liu et al. May 2009 A1
20090131886 Liu et al. May 2009 A1
20090149878 Truckai et al. Jun 2009 A1
20090222053 Gaunt et al. Sep 2009 A1
20090312764 Marino Dec 2009 A1
20100010392 Skelton et al. Jan 2010 A1
20100016929 Prochazka Jan 2010 A1
20100023006 Ellman Jan 2010 A1
20100023065 Welch et al. Jan 2010 A1
20100082033 Germain Apr 2010 A1
20100094269 Pellegrino et al. Apr 2010 A1
20100114098 Carl May 2010 A1
20100145424 Podhajsky et al. Jun 2010 A1
20100179556 Scribner et al. Jul 2010 A1
20100185082 Chandran et al. Jul 2010 A1
20100185161 Pellegrino et al. Jul 2010 A1
20100211076 Germain et al. Aug 2010 A1
20100222777 Sutton et al. Sep 2010 A1
20100261989 Boseck et al. Oct 2010 A1
20100261990 Gillis et al. Oct 2010 A1
20100298832 Lau et al. Nov 2010 A1
20100324506 Pellegrino et al. Dec 2010 A1
20110022133 Diederich et al. Jan 2011 A1
20110034884 Pellegrino et al. Feb 2011 A9
20110040362 Godara et al. Feb 2011 A1
20110077628 Hoey et al. Mar 2011 A1
20110087314 Diederich et al. Apr 2011 A1
20110118735 Abou-Marie et al. May 2011 A1
20110196361 Vilims Aug 2011 A1
20110206260 Bergmans et al. Aug 2011 A1
20110264098 Cobbs Oct 2011 A1
20110276001 Schultz et al. Nov 2011 A1
20110295261 Germain Dec 2011 A1
20110319765 Gertner et al. Dec 2011 A1
20120029420 Vilims Feb 2012 A1
20120136346 Condie et al. May 2012 A1
20120136348 Condie et al. May 2012 A1
20120172858 Harrison et al. Jul 2012 A1
20120172859 Condie et al. Jul 2012 A1
20120196251 Taft et al. Aug 2012 A1
20120197344 Taft et al. Aug 2012 A1
20120203219 Evans et al. Aug 2012 A1
20120226273 Nguyen et al. Sep 2012 A1
20120239050 Linderman Sep 2012 A1
20120265186 Burger et al. Oct 2012 A1
20120330180 Pellegrino et al. Dec 2012 A1
20120330300 Pellegrino et al. Dec 2012 A1
20120330301 Pellegrino et al. Dec 2012 A1
20130006232 Pellegrino et al. Jan 2013 A1
20130006233 Pellegrino et al. Jan 2013 A1
20130012933 Pellegrino et al. Jan 2013 A1
20130012935 Pellegrino et al. Jan 2013 A1
20130012936 Pellegrino et al. Jan 2013 A1
20130012951 Linderman Jan 2013 A1
20130079810 Isenberg Mar 2013 A1
20130231654 Germain Sep 2013 A1
20130103022 Sutton et al. Oct 2013 A1
20130261507 Diederich et al. Oct 2013 A1
20130324994 Pellegrino et al. Dec 2013 A1
20130324996 Pellegrino et al. Dec 2013 A1
20130324997 Pellegrino et al. Dec 2013 A1
20130345765 Brockman et al. Dec 2013 A1
20140031715 Sherar et al. Jan 2014 A1
20140039500 Pellegrino et al. Feb 2014 A1
20140046245 Cornacchia Feb 2014 A1
20140066913 Sherman Mar 2014 A1
20140088575 Loeb Mar 2014 A1
20140148801 Asher et al. May 2014 A1
20140148805 Stewart et al. May 2014 A1
20140171942 Werneth et al. Jun 2014 A1
20140221967 Childs et al. Aug 2014 A1
20140236144 Krueger et al. Aug 2014 A1
20140243823 Godara et al. Aug 2014 A1
20140243943 Rao et al. Aug 2014 A1
20140257265 Godara et al. Sep 2014 A1
20140271717 Goshayeshgar et al. Sep 2014 A1
20140276728 Goshayeshgar et al. Sep 2014 A1
20140276744 Arthur et al. Sep 2014 A1
20140288544 Diederich et al. Sep 2014 A1
20140288546 Sherman et al. Sep 2014 A1
20140296850 Condie et al. Oct 2014 A1
20140316405 Pellegrino et al. Oct 2014 A1
20140324051 Pellegrino et al. Oct 2014 A1
20140336630 Woloszko et al. Nov 2014 A1
20140336667 Pellegrino et al. Nov 2014 A1
20140364842 Werneth et al. Dec 2014 A1
20150005614 Heggeness et al. Jan 2015 A1
20150005767 Werneth et al. Jan 2015 A1
20150045783 Edidin Feb 2015 A1
20150057658 Sutton et al. Feb 2015 A1
20150065945 Zarins et al. Mar 2015 A1
20150073515 Turovskiy et al. Mar 2015 A1
20150141876 Diederich May 2015 A1
20150157402 Kunis et al. Jun 2015 A1
20150164546 Pellegrino et al. Jun 2015 A1
20150196358 Goshayeshgar Jul 2015 A1
20150216588 Deem et al. Aug 2015 A1
20150231417 Metcalf et al. Aug 2015 A1
20150272655 Condie et al. Oct 2015 A1
20150297246 Patel et al. Oct 2015 A1
20150335349 Pellegrino et al. Nov 2015 A1
20150335382 Pellegrino et al. Nov 2015 A1
20150342660 Nash Dec 2015 A1
20150342670 Pellegrino et al. Dec 2015 A1
20150359586 Heggeness Dec 2015 A1
20150374432 Godara et al. Dec 2015 A1
20150374992 Crosby et al. Dec 2015 A1
20150374995 Foreman et al. Dec 2015 A1
20160000601 Burger et al. Jan 2016 A1
20160001096 Mishelevich Jan 2016 A1
20160002627 Bennett et al. Jan 2016 A1
20160008593 Cairns Jan 2016 A1
20160008618 Omar-Pasha Jan 2016 A1
20160008628 Morries et al. Jan 2016 A1
20160016012 Youn et al. Jan 2016 A1
20160022988 Thieme et al. Jan 2016 A1
20160022994 Moffitt et al. Jan 2016 A1
20160024208 MacDonald et al. Jan 2016 A1
20160029930 Plumley et al. Feb 2016 A1
20160030276 Spanyer Feb 2016 A1
20160030408 Levin Feb 2016 A1
20160030748 Edgerton et al. Feb 2016 A1
20160030765 Towne et al. Feb 2016 A1
20160051831 Lundmark et al. Feb 2016 A1
20160059007 Koop Mar 2016 A1
20160074068 Patwardhan Mar 2016 A1
20160074279 Shin Mar 2016 A1
20160074661 Lipani Mar 2016 A1
20160081716 Boling et al. Mar 2016 A1
20160095721 Schell et al. Apr 2016 A1
20160106985 Zhu Apr 2016 A1
20160106994 Crosby et al. Apr 2016 A1
20160113704 Godara et al. Apr 2016 A1
20160115173 Bois et al. Apr 2016 A1
20160136310 Bradford et al. May 2016 A1
20160144182 Bennett et al. May 2016 A1
20160144187 Caparso et al. May 2016 A1
20160158551 Kent et al. Jun 2016 A1
20160166835 De Ridder Jun 2016 A1
20160175586 Edgerton et al. Jun 2016 A1
20160199097 Linderman et al. Jul 2016 A1
20160213927 McGee et al. Jul 2016 A1
20160220393 Slivka et al. Aug 2016 A1
20160220638 Dony et al. Aug 2016 A1
20160220672 Chalasani et al. Aug 2016 A1
20160228131 Brockman et al. Aug 2016 A1
20160228696 Imran et al. Aug 2016 A1
20160235471 Godara et al. Aug 2016 A1
20160235474 Prisco et al. Aug 2016 A1
20160243353 Ahmed Aug 2016 A1
20160246944 Jain et al. Aug 2016 A1
20160250469 Kim et al. Sep 2016 A1
20160250472 Carbunaru Sep 2016 A1
20160262830 Werneth et al. Sep 2016 A1
20160271405 Angara et al. Sep 2016 A1
20160278791 Pellegrino et al. Sep 2016 A1
20160278846 Harrison et al. Sep 2016 A1
20160279190 Watts et al. Sep 2016 A1
20160279408 Grigsby et al. Sep 2016 A1
20160279411 Rooney et al. Sep 2016 A1
20160279441 Imran Sep 2016 A1
20160302925 Keogh et al. Oct 2016 A1
20160310739 Burdick et al. Oct 2016 A1
20160317053 Srivastava Nov 2016 A1
20160317211 Harrison et al. Nov 2016 A1
20160317621 Bright Nov 2016 A1
20160324541 Pellegrino et al. Nov 2016 A1
20160324677 Hyde et al. Nov 2016 A1
20160325100 Lian et al. Nov 2016 A1
20160339251 Kent et al. Nov 2016 A1
20160354093 Pellegrino et al. Dec 2016 A1
20160354233 Sansone et al. Dec 2016 A1
20160367797 Eckermann Dec 2016 A1
20160367823 Cowan et al. Dec 2016 A1
20160375259 Davis et al. Dec 2016 A1
20170001026 Schwarz et al. Jan 2017 A1
20170007277 Drapeau et al. Jan 2017 A1
20170014169 Dean et al. Jan 2017 A1
20170027618 Lee et al. Feb 2017 A1
20170028198 Degiorgio et al. Feb 2017 A1
20170028201 Howard Feb 2017 A1
20170035483 Crainich et al. Feb 2017 A1
20170036009 Hughes et al. Feb 2017 A1
20170036025 Sachs et al. Feb 2017 A1
20170036033 Perryman et al. Feb 2017 A9
20170042834 Westphal et al. Feb 2017 A1
20170049503 Cosman Feb 2017 A1
20170049507 Cosman Feb 2017 A1
20170049513 Cosman Feb 2017 A1
20170050017 Cosman Feb 2017 A1
20170050021 Cosman Feb 2017 A1
20170050024 Bhadra et al. Feb 2017 A1
20170266419 Goshayeshgar Feb 2017 A1
20170119461 Godara et al. May 2017 A1
20170128080 Torrie May 2017 A1
20170135742 Lee et al. May 2017 A1
20170181788 Dastjerdi et al. Jun 2017 A1
20170202613 Pellegrino et al. Jul 2017 A1
20180021048 Pellegrino et al. Jan 2018 A1
20180042656 Edidin Feb 2018 A1
20180103964 Patel et al. Apr 2018 A1
20180153604 Ayvazyan et al. Jun 2018 A1
20180161047 Purdy et al. Jun 2018 A1
20180193088 Sutton et al. Jul 2018 A1
20190029698 Pellegrino et al. Jan 2019 A1
20190038296 Pellegrino Feb 2019 A1
20190038343 Sutton et al. Feb 2019 A1
20190038344 Pellegrino Feb 2019 A1
20190038345 Pellegrino Feb 2019 A1
20190090933 Pellegrino et al. Mar 2019 A1
20190110833 Pellegrino et al. Apr 2019 A1
20190118003 Diederich et al. Apr 2019 A1
20190118004 Diederich et al. Apr 2019 A1
20190118005 Diederich et al. Apr 2019 A1
20190282268 Pellegrino et al. Sep 2019 A1
20190290296 Patel et al. Sep 2019 A1
Foreign Referenced Citations (46)
Number Date Country
43 23 585 Jan 1995 DE
0 040 658 Dec 1981 EP
0040658 Dec 1981 EP
0584959 Mar 1994 EP
0597463 May 1994 EP
0880938 Dec 1998 EP
1 013 228 Jun 2000 EP
1013228 Jun 2000 EP
1 059 067 Dec 2000 EP
1059067 Dec 2000 EP
1059087 Dec 2000 EP
2913081 Jan 2017 EP
6-47058 Feb 1994 JP
6-47058 Feb 1994 JP
10-290806 Nov 1998 JP
2001-037760 Feb 2001 JP
2005-169012 Jun 2005 JP
9636289 Nov 1996 WO
WO9636289 Nov 1996 WO
98-27876 Jul 1998 WO
WO9827876 Jul 1998 WO
WO9834550 Aug 1998 WO
WO9919025 Apr 1999 WO
WO9944519 Sep 1999 WO
WO9948621 Sep 1999 WO
WO0021448 Apr 2000 WO
WO0033909 Jun 2000 WO
WO0049978 Aug 2000 WO
WO0056237 Sep 2000 WO
WO0067648 Nov 2000 WO
WO0067656 Nov 2000 WO
WO0101877 Jan 2001 WO
WO0145579 Jun 2001 WO
0157655 Aug 2001 WO
WO0157655 Aug 2001 WO
WO0205699 Jan 2002 WO
WO0205897 Jan 2002 WO
0228302 Apr 2002 WO
WO0228302 Apr 2002 WO
WO2002026319 Apr 2002 WO
02054941 Jul 2002 WO
WO02054941 Jul 2002 WO
02-067797 Sep 2002 WO
WO02067797 Sep 2002 WO
WO02096304 Dec 2002 WO
WO 2009124192 Oct 2009 WO
Non-Patent Literature Citations (49)
Entry
Bogduk, N., The anatomy of the lumbar intervertebral disc syndrome, Med J. Aust. 1976, vol. 1, No. 23, pp. 878-881.
A Novel Approach for Treating Chronic Lower Back Pain, Abstract for Presentation at North American Spine Society 26th Annual Meeting in Chicago, IL on Nov. 4, 2011.
Antonacci, M. Darryl et al.; Innervation of the Human Vertebral Body: A Histologic Study; Journal of Spinal Disorder, vol. 11, No. 6, pp. 526-531, 1998 Lippincott Williams & Wilkins, Philadelphia.
Arnoldi, Carl C.; Intraosseous Hypertension—A Possible Cause of Low Back Pain?; Clinical Orthopedics and Related Research, No. 115, Mar.-Apr. 1976.
Bailey, Jeannie F., “Innervation Patterns of PGP 9.5-Positive Nerve Fibers within the Human Lumbar Vertebra, Journal of Anatomy”, (2011) 218, pp. 263-270, San Francisco, California.
Bergeron et al., “Fluoroscopic-guided radiofrequency ablation of the basivertebral nerve: application and analysis with multiple imaging modalities in an ovine model,” Thermal Treatment of Tissue: Energy Delivery and Assessment III, edited by Thomas P. Ryan, Proceedings of SPIE, vol. 5698 (SPIE, Bellingham, WA, 2005) pp. 156-167.
Bogduk, Nikolai, et al.; Technical Limitations to the efficacy of Radiofrequency Neurotomy for Spinal Pain; Neurosurgery vol. 20, No. 4, 1987.
Choy, Daniel SS.J. et al.; Percutaneous Laser Disc Decompression, A New Therapeutic Modality; Spine vol. 17, No. 8, 1992.
Cosman, E.R. et al., Theoretical Aspects of Radiofrequency Lesions in the Dorsal Root Entry Zone. Neurosurgery, vol. 1, No. 6, 1984, pp. 945-950.
Deardorff, Dana L. et al.; Ultrasound applicators with internal cooling for interstitial thermal therapy; SPIE vol. 3594, 1999.
Dupuy, D.E. et al. Radiofrequency ablation of spinal tumors: Temperature distribution in the spinal canal AJR, vol. 175, pp. 1263-1266, Nov. 2000.
Dupuy, Damian E.; Radiofrequency Ablation: An Outpatient Percutaneous Treatment; Medicine and Health/Rhode Island vol. 82, No. 6, Jun. 1999.
Deramond, H. et al., Temperature Elevation Caused by Bone Cement Polymerization During Vertebroplasty, Bone, Aug. 1999, pp. 17S-21S, vol. 25, No. 2, Supplement.
Diederich, C. J. et al., “IDTT Therapy in Cadaveric Lumbar Spine: Temperature and thermal dose distributions, Thermal Treatment of Tissue: Energy Delivery and Assessment,” Thomas P. Ryan, Editor, Proceedings of SPIE vol. 4247:104-108 (2001).
Diederich, Chris J. et al.; Ultrasound Catheters for Circumferential Cardiac Ablation; SPIE vol. 3594 (1999).
Esses, Stephen I. et al.; Intraosseous Vertebral Body Pressures; Spine vol. 17 No. 6 Supplement 1992.
FDA Response to 510(k) Submission by Relievant Medsystems, Inc. submitted on Sep. 27, 2007 (date stamped on Oct. 5, 2007) and associated documents.
Fras M.D., Christian et al., “Substance P-containing Nerves within the Human Vertebral Body: An Immunohistochemical Study of the Basivertebral Nerve”, The Spine Journal 3, 2003, pp. 63-67.
Goldberg, S.N. et al., Tissue ablation with radiofrequency: Effect of probe size, gauge, duration, and temperature on lesion volume, Acad. Radiol., vol. 2, pp. 399-404 (1995).
Hanai, Kenji et al.; Simultaneous Measurement of Intraosseous and Cerebrospinal Fluid Pressures in the Lumbar Region; Spine vol. 10, No. 1, 1985.
Heggeness, Michael H. et al., The Trabecular Anatomy of Thoracolumbar Vertebrae: Implications for Burst Fractures, Journal of Anatomy, 1997, pp. 309-312, vol. 191, Great Britain.
Heggeness, Michael H. et al. Discography Causes End Plate Deflection; Spine vol. 18, No. 8, pp. 1050-1053, 1993, J.B. Lippincott Company.
Hoopes et al., “Radiofrequency Ablation of the Basivertebral Nerve as a Potential Treatment of Back Pain: Pathologic Assessment in an Ovine Model,” Thermal Treatment of Tissue: Energy Delivery and Assessment III, edited by Thomas P. Ryan, Proceedings of SPIE, vol. 5698 (SPIE, Bellingham, WA, 2005) pp. 168-180.
Houpt, Jonathan C. et al.; Experimental Study of Temperature Distributions and Thermal Transport During Radiofrequency Current Therapy of the Intervertebral Disc; Spine vol. 21, No. 15, pp. 1808-1813, 1996. Lippincott-Raven Publishers.
Kleinstueck, Frank S. et al.; Acute Biomechanical and Histological Effects of Intradiscal Electrothermal Therapy on Human Lumbar Discs; Spine vol. 26, No. 20, pp. 2198-2207; 2001, Lippincott Williams & Wilkins, Inc.
Kopecky, Kenyon K. et al. “Side-Exiting Coaxial Needle for Aspiration Biopsy”—AJR—1996; 167, pp. 661-662.
Lehmann, Justus F. et al.; Selective Heating Effects of Ultrasound in Human Beings; Archives of Physical Medicine & Rehabilitation Jun. 1966.
Letcher, Frank S. et al.; The Effect of Radiofrequency Current and Heat on Peripheral Nerve Action Potential in the Cat; U.S. Naval Hospital, Philadelphia, PA. (1968).
Lundskog, Jan; Heat and Bone Tissue-/an experimental investigation of the thermal properties of bone tissue and threshold levels for thermal injury; Scandinavian Journal of Plastic and Reconstructive Surgery Supplemental 9, From the Laboratory of Experimental Biology, Department of anatomy, University of Gothenburg, Gothenburg, Sweden, Goteborg 1972.
Martin, J.B. et al., Vertebroplasty: Clinical Experience and Follow-up Results, Bone, Aug. 1999, pp. 11S-15S, vol. 25, No. 2, Supplement.
Massad, Malek M.D. et al.; Endoscopic Thoracic Sympathectomy: Evaluation of Pulsatile Laser, Non-Pulsatile Laser, and Radiofrequency-Generated Thermocoagulation; Lasers in Surgery and Medicine; 1991; pp. 18-25.
Mehta, Mark et al.; The treatment of chronic back pain; Anaesthesia, 1979, vol. 34, pp. 768-775.
Nau, William H., Ultrasound interstitial thermal therapy (USITT) in the prostate; SPIE vol. 3594, Jan. 1999.
Rashbaum, Ralph F.; Radiofrequency Facet Denervation A Treatment alternative in Refractory Low Back Pain with or without Leg Pain; Orthopedic Clinics of North America—vol. 14, No. 3, Jul. 1983.
Rosenthal, D.I., Seminars in Musculoskeletal Radiology, vol. 1, No. 2., pp. 265-272 (1997).
Ryan et al., “Three-Dimensional Finite Element Simulations of Vertebral Body Thermal Treatment,” Thermal Treatment of Tissue: Energy Delivery and Assessment III, edited by Thomas P. Ryan, Proceedings of SPIE, vol. 5698 (SPIE, Bellingham, WA, 2005) pp. 137-155.
Shealy, C. Norman; Percutaneous radiofrequency denervation of spinal facets Treatment for chronic back pain and sciatica; Journal of Neurosurgery/vol. 43/Oct. 1975.
Sherman, Mary S.; The Nerves of Bone, The Journal of Bone and Joint Surgery, Apr. 1963, pp. 522-528, vol. 45-A, No. 3.
Solbiati, L. et al. Hepatic metastases: Percutaneous radio-frequency ablation with cooled-tip electrodes. Interventional Radiology, vol. 205, No. 2, pp. 367-373 (1997).
Stanton, Terry, “Can Nerve Ablation Reduce Chronic Back Pain?” AAOS Now Jan. 2012.
The AVAmax System—Cardinal Health Special Procedures, Lit. No. 25P0459-01—www.cardinal.com (copyright 2007).
Tillotson, L. et al. Controlled thermal injury of bone: Report of a percutaneous technique using radiofrequency electrode and generator. Investigative Radiology, Nov. 1989, pp. 888-892.
Troussier, B. et al.; Percutaneous Intradiscal Radio-Frequency Thermocoagulation A Cadaveric Study; Spine vol. 20, No. 15, pp. 1713-1718, 1995, Lippincott-Raven Publishers.
Ullrich, Jr., Peter F., “Lumbar Spinal Fusion Surgery” Jan. 9, 2013, Spine-Health (available via wayback machine Internet archive at http://web.archive.org/web/20130109095419/http://www/spine-health.com/treatment/spinal-fusion/lumbar-spinal-fusion-surgery).
Osteocool Pain Management Brochure, Baylis Medical, copyright 2011.
Gehl, J., “Electroporation: theory and methods, perspectives for drug delivery, gene therapy, and research”, Acta Physiol. Scand., vol. 177, pp. 437-447 (2003).
Modic MT et al.; “Degenerative disk disease: assessment of changes in vertebral body marrow with MR imaging”, Radiology, vol. 166, pp. 193-199 (1988).
Weishaupt, D et al,; “Painful Lumbar Disk Derangement: Relevance of Endplate Abnormalities at MR Imaging”, Radiology, vol. 218(2), pp. 420-427 (2001).
E.R. Cosman et al. Theoretical aspects of radiofrequency lesions in the dorsal root entry zone. Neurosurgery, vol. 15, No. 6, pp. 945-950 (1984).
Divisions (2)
Number Date Country
Parent 13541591 Jul 2012 US
Child 11123766 US
Parent 10260879 Sep 2002 US
Child 11123766 US
Reissues (2)
Number Date Country
Parent 11123766 May 2005 US
Child 15469315 US
Parent 11123766 May 2005 US
Child 13541591 US